Skip to primary content
Skip to secondary content

Didymus Judas Thomas' Hipocritical Oath Blog

Stanislaw Rajmund Burzynski, Stanislaw R. Burzynski, Stanislaw Burzynski, Stan R. Burzynski, Stan Burzynski, S. R. BURZYNSKI, S. Burzynski, Arthur Burzynski, Hippocrates Hypocrite Hypocrites Critic Critics Critical HipoCritical

Didymus Judas Thomas' Hipocritical Oath Blog

Main menu

  • Home
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • 1
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 1998 (1/15/1998)
  • 1999 (2/1999) Volume 74 Number 2 pg. 137 – 3 pgs.
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • About
  • List of Articles

Tag Archives: remained

Cancer: It’s what’s Best for Business (WW3 – World War Hypocrisy)

Posted on December 14, 2013 by didymusjudasthomas
Reply

20131217-101211.jpg
David H. Gorski, M.D., Ph.D., F.A.C.S., is a racist and a natural born killer

That’s right !

Dr. Gorski hates #cancer

He’s a bigot when it comes to breast cancer

Gorski sleeps, breathes, and blogs about breast cancer

He is an academic surgical oncologist specializing in breast surgery and oncologic surgery (Surgical Oncology Attending) at the Barbara Ann Karmanos Cancer Institute, Detroit, Michigan specializing in breast cancer surgery, where he also serves as team leader for the Breast Cancer Multidisciplinary Team (MDT) at the Barbara Ann Karmanos Cancer Center, Co-Chair, Cancer Committee, Barbara Ann Karmanos Cancer Center, medical director of the Alexander J. Walt Comprehensive Breast Center at the Barbara Ann Karmanos Cancer Center (2010-present), Co-Leader of the Breast Cancer Biology Program, and the American College of Surgeons Committee on Cancer (ACS CoC) Cancer Liaison Physician as well as Associate Professor of Surgery at the Wayne State University School of Medicine; Faculty (2008-present), and member of the faculty of the Graduate Program in Cancer Biology at Wayne State University, MiBOQI project director (clinical champion) for Karmanos Cancer Center, site project director of the Michigan Breast Oncology Quality Initiative, University of Michigan, Ann Arbor, Michigan, a partnership between Karmanos and the University of Michigan, the new program co-director (Co-Medical Director) of the Michigan Breast Oncology Quality Initiative (MiBOQI); a state-wide initiative to improve the quality of breast cancer care using evidence-based guidelines, serves as the co-director of the Comprehensive Breast Center and is co-leader of the Breast Cancer Biology Program at Karmanos and Wayne State University School of Medicine, a Wayne State University Physician Group surgeon and chief of the Section of Breast Surgery (Breast Surgery Section) for the Wayne State University School of Medicine (2009-present), serves as an associate professor of surgery and Oncology at Wayne State University School of Medicine, Detroit, Michigan, and Treasurer and on the Board of Directors, and also serves the Institute for Science in Medicine as head of its childhood immunization committee

Prior to joining Karmanos and Wayne State University School of Medicine, was an associate professor of surgery at The Cancer Institute of New Jersey and the UMDNJ-Robert Wood Johnson Medical School in New Brunswick, NJ, as well as a member of the Joint Graduate Program in Cell & Developmental Biology at Rutgers University in Piscataway, N.J.

1984 – Graduation with Honors and High Distinction in Chemistry

1994 – MetroHealth Medical Center Resident Research

He attended the University of Michigan Medical School, received his B.S. in chemistry from the University of Michigan, Ann Arbor, Michigan, medical degree (M.D.) from the University of Michigan Medical School, Ann Arbor, Michigan, University of Chicago Fellowship, Surgical Oncology, Case Western Reserve University / University Hospitals Case Medical Center Internship, General Surgery, Case Western: Reserve University / University Hospitals Case Medical Center Residency, General Surgery, and received his Ph.D. in cellular physiology at Case Western Reserve University, Cleveland, Ohio

1998 – American Board of Surgery

Assistant Professor of Surgery UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey

1999 – 2006: Assistant Professor of Surgery

1999 – 2008: Active, Surgical Oncology and General Surgery

2005 – 2006: Active, Surgical Oncology and General Surgery

2007 – American Society of Clinical Oncology Advanced Clinical Research

2007 – Conquer Cancer Foundation of ASCO and Breast Cancer Research Foundation Advanced Clinical Research Award in Breast Cancer

2006 – 2008: Associate Professor of Surgery

Faculty, General Surgery, St. Peter’s University Hospital, New Brunswick, New Jersey

Attending Surgeon, Trauma Services, Lutheran General Hospital, Park Ridge, Illinois

2015 – Michigan State Medical License (Active through)

2015 – Ohio State Medical License (Active through)

Managing Editor of the Science-Based Medicine weblog, as well as a once-weekly contributor

SBM exists to take a skeptical, science-based view of medicine in general and in particular the infiltration of pseudoscientific practices into medicine, even in academic medical centers

These entities must have felt lucky to add a University of Michigan alum to their toolbox, a wolverine; a creature also known as a glutton or skunk bear

Who would doubt that Gorski would be a glutton for punishment when it comes to raising a big stink about breast cancer issues ?

Surely he was aware: Detroit, Michigan; the most populous city in the state of Michigan, with a population of 701,475 (2012) (9,883,360 – Michigan), 575,321 (81.4%) being African American (Black); a little less than six times the national average (82.7% – 2010 / about 83% – 2012) (Michigan – 14.2% – 2010), 369,616 Females (52.7% – 2012 / 53% – 2010) (Michigan 50.9%)

No doubt he knew that the most recent American Cancer Society Cancer Facts & Figures, noted:
——————————————————————
• Studies have documented unequal receipt of prompt, high-quality treatment for African American women compared to white women

• African Americans more likely to be diagnosed at later stage of disease when treatment choices are more limited and less effective

• African Americans and other racial minorities are underrepresented in clinical trials, which makes it more difficult to assess efficacy of cancer therapies among different racial/ethnic groups

• African Americans have highest death rate and shortest survival of any racial and ethnic group in US for most cancers

• Life expectancy lower for African Americans than whites among women (77.2 vs. 80.9 years)

• Higher death rate in African American women compared to white women occurs despite lower cancer incidence rate

• Racial difference in overall cancer death rates is due largely to cancers of the breast and colorectum in women

• African American women have higher death rates overall and for breast and several other cancer sites

• African Americans continue to have lower 5-year survival overall:
69% – whites
60% – African Americans
and for each stage of diagnosis for most cancer sites

• Evidence aggressive tumor characteristics more common in African American than white women
——————————————————————
Gorski worked tirelessly to address the problem, by appearing on TV, radio, Internet radio, in articles and on his blogs

Soon, the locals were remarking about the “Gorski Patient Group” web-site which was set up to display anecdotal stories of breast cancer patients who were “cured” by Gorski

How has his hard work paid off ?
——————————————————————
Are these Dr. David H. Gorski’s “success stories” ?
——————————————————————
African American women breast cancer death rates per 100,000 (MICHIGAN)
—————————————————————–
34.3☝2005_-_2009 (State with 11 most) 2013-2014
33.8👇2003_-_2007 (State with 11 most) 2011-2012
34.7👇2001_-_2005 (State with 17 most) 2009-2010
35.4👇2000_-_2003 (State with 19 most) 2007-2008
36.2👇1997_-_2001 (State tied with 20 most) 2005-2006
——————————————————————
BREAST CANCER
——————————————————————
WHITE-INCIDENCE-MICHIGAN (per 100,000)
——————————————————————
118.7👇2006_-_2010 (2013-2014)
120.1👇2004_-_2008 Incidence (2011-2012)
124.3👇2002_-_2006 (2009-2010)
129.9👇2000_-_2004 (2007-2008)
133.9☝1998_-_2002 (2005-2006)
132.1☝1996_-_2000 (2003-2004)
——————————————————————
WHITE-MORTALITY-MICHIGAN (per 100,000)
——————————————————————
22.8👇2006_-_2010 (2013-2014)
23.4👇2003_-_2007 Mortality (2011-2012)
23.8👇2002_-_2006 (2009-2010)
24.6👇2000_-_2004 (2007-2008)
25.9👇1998_-_2002 (2005-2006)
27.3👇1996_-_2000 (2003-2004)
——————————————————————
AFRICAN AMERICAN-INCIDENCE-MICHIGAN (per 100,000)
——————————————————————
119.4☝2006_-_2010 (2013-2014)
119.2👇2004_-_2008 Incidence (2011_-_2012)
121.0☝2002_-_2006 (2009-2010)
119.0👇2000_-_2004 (2007-2008)
120.6👇1998_-_2002 (2005-2006)
121.4☝1996_-_2000 (2003-2004)
——————————————————————
AFRICAN AMERICAN-MORTALITY-MICHIGAN (per 100,000)
——————————————————————
34.3☝2006_-_2010 (2013-2014)
33.8👇2003_-_2007 Mortality (2011-2012)
34.6👇2002_-_2006 (2009-2010)
35.0👇2000_-_2004 (2007-2008)
36.0👇1998_-_2002 (2005-2006)
36.9👇1996_-_2000 (2003-2004)
——————————————————————
HISPANIC-INCIDENCE-MICHIGAN (per 100,000)
——————————————————————
80.1👇2006_-_2010 (2013-2014)
92.7☝2004_-_2008 Incidence (2011-2012)
——————————————————————
HISPANIC-MORTALITY-MICHIGAN (per 100,000)
——————————————————————
15.8☝2006_-_2010 (2013-2014)
14.26☝2003_-_2007 Mortality (2011-2012)
——————————————————————
INCIDENCE-MICHIGAN (per 100,000) COMBINED
——————————————————————
119.4☝2006_-_2010 AFRICAN AMERICAN (2013-2014)
118.7👇2006_-_2010 WHITE (2013-2014)
80.1👇2006_-_2010 HISPANIC (2013-2014)
——————————————————————
MORTALITY-MICHIGAN (per 100,000) COMBINED
——————————————————————
34.3☝2006_-_2010 AFRICAN AMERICAN (2013-2014)
22.8👇2006_-_2010 WHITE (2013-2014)
15.8☝2006_-_2010 HISPANIC (2013-2014)
——————————————————————
MICHIGAN – Estimated New Breast Cancer Cases:
——————————————————————
8,140☝2013 (State with 8th most)
7,710👇2012 (State with 8th most)
7,890☝2011 (State with 8th most)
7,340☝2010 (State with 8th most)
6,480☝2009 (State with 8th most)
6,120👇2008 (State with 9th most)
7,210👇2005 (State with 9th most)
7,270👇2004 (State with 9th most)
7,500☝2003 (State with 8th most)
7,300☝2002 (State with 8th most)
——————————————————————
Are these Dr. David H. Gorski’s “success stories” ?
——————————————————————
MICHIGAN – Estimated Breast Cancer Deaths:
——————————————————————
1,360☝2013 (State with 8th most)
1,350☝2012 (State with 8th most)
1,320 – 2011 (State with 9th most)
1,320👇2010 (State with 10th most)
1,350☝2009 (State with 9th most)
1,310 👇2008 (State with 9th most)
1,320 👇2007 (State with 9th most)
1,360 👇2006 (State with 9th most)
1,380☝2005 (State with 9th most)
1,350👇2004 (State with 9th most)
1,400 – 2003 (State tied with 8th most)
1,400☝2002 (State tied with 8th most)
——————————————————————
MICHIGAN – Cancer Incidence Rates
——————————————————————
120.3 – 2013 (State with 32nd most)
120.3👇2012 (State with 30th most)
122.2👇2011 (State with 24th most)
124.2👇2010 (State with 17th most)
127.0👇2009 (State with 11th most)
128.8👇2008 (State with 13th most)
129.4👇2007 (State tied with 18th most)
132.4👇2006 (State with 14th most)
133.5☝2005 (State with 13th most)
132.0☝1996_-_2000 (State with 14th most) 2004
129.8☝1995_-_1999 (State with 23rd most)(31st State’s) 2003
109.9👇1994_-_1998 Michigan – Cancer Incidence Rates (2002)
132.0☝1996_-_2000 (State with 14th most) (2004)
129.8☝1995_-_1999 (State with 23rd most) (2003)
109.9☝1994_-_1998 (State with 20th most) (2002)
——————————————————————
MICHIGAN – Cancer Death Rates:
——————————————————————
24.0👇2013 (State tied with 11th most)
24.4👇2012 (State tied with 13th most)
24.5👇2011 (State tied with 16th most)
25.1👇2010 (State tied with 12th most)
25.3👇2009 (State tied with 17th most)
25.8👇2008 (State tied with 18th most)
26.6👇2007 (State tied with 14th most)
27. 5 – 2006 (State tied with 12th most)
27.5👇2005 (State tied with 13th most)
28.4👇1996_-_2000 (State tied with 14th most) (2004)
29.5☝1995_-_1999 (State tied with 14th most) 2003
24.8☝1994_-_1998 (State with 14th most) 2002
——————————————————————
The problem, is that, when the Hippocratic Oath
was mentioned, Gorski may have opted for the Hypocrite Oath

Rather than address the BILLIONS of dollars in fines which Big Pharma racked up, and Pharma’s seeming dedication to getting members of the unwitting public, to take medications for symptoms which they were not approved for; and thus possibly experience adverse effects those drugs cause, Gorski chose to NOT comment about his goose that might lay the golden (parachute) nest egg

Instead, he tried the Tricky-Dicky trickle-down theory of Hackademic Mudicine (“Quackademic Medicine”); which did NOT work when Richard Milhous (“War on Cancer”) Nixon was told:

“There’s a cancer on the Presidency”

What Gorski seems hilariously oblivious to, is that his opprobrium; to turn a phrase, applies to him:
——————————————————————
(.3:16)
——————————————————————
When he mentions:

“ineffective and potentially harmful medical practices that were not, that are not supported by evidence”

he may as well be saying, in regards to surgery, chemotherapy, and radiation:

“ineffective and potentially harmful medical practices that were, that are supported by evidence“

(the evidence that they do NOT work for everyone)
——————————————————————
(.3:42)
——————————————————————
To use his own words, he seems:

“confused, at best”
——————————————————————
(.4:45)
——————————————————————
He also displays:

“an animosity toward reason”
——————————————————————
(.4:49)
——————————————————————
“Nothing’s changed within 30 years

If anything, it’s worse”
——————————————————————
(.6:45)
——————————————————————
He states:

“Alternative = unproved”

There goes “Alternative Rock,” or the “alternative” to an attempted Gorski joke: “happiness is a warm gun”

I’m somewhat surprised that Gorski has yet to classify antineoplastons as “Homeopathy: Ultra-diluted chemotherapy”
——————————————————————
(28:15)
——————————————————————
But he does rant that rival Cleveland Clinic where he had his residency, has been infiltrated by the Q.M.
——————————————————————
(39:10)
——————————————————————
And that his alma-mater, the University of Michigan has also queued in the “Quackademic” line
——————————————————————
(44:00)
——————————————————————
He bemoans the mighty wolverine:

“Again my alma-mater”

“I hang my head in shame”
——————————————————————
(44:10)
——————————————————————
And to add injury to insult, his “former employer,” UMDNJ (University of Medicine and Dentistry of New Jersey)-Robert Wood Johnson Medical School, New Brunswick, New Jersey, has also been bitten by the Quackademic Duck

I’m sure Gorski will be able to formulate a usual factoid #fail for his #failure to “cure” cancer, vis-a-vis “Orac”, the literary Hack, braying in the wilderness and awaiting his Red Badge of Courage

Maybe “too many people copulating” in Detroit, or too many Louisiana hurricane Katrina survivors added to the sandbox

Is Gorski a racist ?

That’s up to all the African American women in Detroit, Michigan, to decide

Maybe he’s just a really bad hypocrite

NOr, maybe he needs to spend less time on the “hypocuresy,” and more time on the “CURE”

Maybe the African American women of Detroit, Michigan, and the United States of America should ask Gorski:

What have you done for me lately ?
——————————————————————

20131218-150634.jpg
——————————————————————
“And, make no mistake about it, antineoplastons (ANPs) are chemotherapy, no matter how much Burzynski tries to claim otherwise”
——————————————————————
NO, Gorski, the United States’ 5th Circuit Court of Appeals claimed that antineoplastons (ANPs) are:

“…an unapproved drug, not ordinary “chemotherapy”

no matter how much YOU try to claim otherwise

What are you ?

A Saul Green closet communist who does NOT believe what the United States’ Federal Courts rule ?

20131218-150702.jpg
——————————————————————

20131218-150719.jpg
——————————————————————
“Indeed, it was a blatant ploy, as Burzynski’s lawyer, Richard Jaffe, acknowledged, referring to one of his clinical trials as a “joke” and the others as a way to make sure there was a constant supply of new cancer patients to the Burzynski Clinic“
——————————————————————

20131218-155354.jpg
——————————————————————
” … in 1997, his medical practice was expanded to include traditional cancer treatment options such as chemotherapy, gene targeted therapy, immunotherapy and hormonal therapy in response to FDA requirements that cancer patients utilize more traditional cancer treatment options in order to be eligible to participate in the Company’s Antineoplaston clinical trials“

“As a result of the expansion of Dr. Burzynski’s medical practice, the financial condition of the medical practice has improved Dr. Burzynski’s ability to fund the Company’s operations”
——————————————————————
GorskGeek, my citations, references, and / or links, beat your NON-citations, NON-references, and / or NON-links
======================================
AMERICAN CANCER SOCIETY:
CANCER FACTS & FIGURES (2002-2014)

======================================
2002_-_2003 – 1 of every 4 deaths
======================================
Deaths – United States of America
——————————————————————
2013 – almost 1,600 a day
2002-2012☝1,500+ a day
——————————————————————
Expected to Die – United States
——————————————————————
2013☝580,350_-_(3,160 more than 2012)
2012☝577,190
_-_(5,240 more than 2011)
2011☝571,950
_-_(2,460 more than 2010)
2010☝569,490
_-_(7,150 more than 2009)
2009👇562,340_-_(3,310 less than 2008)
2008☝565,650_-_(6,000 more than 2007)
2007👇559,650_-_(5,180 less than 2006)
2006👇564,830_-_(5,450 less than 2005)
2005☝570,280_-_(6,580 more than 2004
2004☝563,700
_-_(7,200 more than 2003)
2003☝556,500
_-_(6,000 more than 2002)
2002
☝555,500
——————————————————————
Estimated All Cancer Deaths (Women)
——————————————————————
2013👇273,430 (1,940 less than 2012)
2012☝275,370 (3,850 more than 2011)
2011☝271,520 (1,230 more than 2010)
2010☝270,290 (490 more than 2009)

2009👇269,800 (1,730 less than 2008)
2008☝271,530 (1,430 more than 2007)
2007👇270,100 (3,460 less than 2006)
2006👇273,560 (1,440 less than 2005)
2005☝275,000 (2,190 more than 2004)
2004☝272,810 (2,210 more than 2003)
2003☝270,600 (3,300 more than 2002)
2002
_-_267,300
——————————————————————
Estimated cancer deaths – African Americans expected to die from cancer:
——————————————————————
2013👇64,645 – 22.6% (2013-2014)
2011☝65,540 (About) (2011-2012)
2009☝63,360 (About) (2009-2010)
2007☝62,780 (About) (2007-2008)

——————————————————————
Estimated Breast Cancer Deaths (Women)
——————————————————————
2013☝39,620 (14%) (110 more than 2012)
2012👇39,510 (14%) (10 less than 2011)
2011👇39,520 (15%) (320 less than 2010)
2010👇39,840 (15%) (330 less than 2009)
2009👇40,170 (15%) (310 less than 2008)
2008☝40,480 (15%) (20 more than 2007)
2007👇40,460 (15%) (2007-2008) (510 less than 2006)
2006☝40,970 (15%) (560 more than 2005)
2005☝40,410 (15%) (300 more than 2004)
2004☝40,110 (15%) (310 more than 2003)
2003☝39,800 (15%) (200 more than 2002)
2002
– 39,600 (15%)
——————————————————————
Estimated Deaths from Breast cancer expected to occur among African American women:
——————————————————————
6,080☝2013 – 19% (2013-2014)
6,040☝2011 – 19% (2011-2012)
6,020☝2009 – 19% (2009-2010)
5,830☝2007 – 19% (2007-2008)
5,640☝(2005-2006)

5,640 – 1969-2002 – 18.4% – 2005 (2005-2006)
======================================
New Cancer Cases Expected to be diagnosed – USA
——————————————————————
2013☝1,660,290 – (21,380 more than 2012)
2012☝1,638,910 – (42,240 more than 2011)
2011☝1,596,670 – (67,160 more than 2010)
2010☝1,529,560 – (49,810 more than 2009)
2009☝1,479,350 – (42,170 more than 2008)

2008👇1,437,180 – ( 7,740 less than 2007)
2007☝1,444,920 – (45,130 more than 2006)
2006☝1,399,790 – (26,880 more than 2005)
2005☝1,372,910 – ( 4,870 more than 2004)
2004☝1,368,030 – (33,930 more than 2003)
2003☝1,334,100 – (49,200 more than 2002)
2002
☝1,284,900
——————————————————————
Estimated New Cancer All (Women)
——————————————————————
2013☝805,500 – (14,760 more than 2012)
2012☝790,740 – (16,370 more than 2011)
2011☝774,370 – (34,430 more than 2010)
2010☝739,940 – (26,720 more than 2009)
2009☝713,220 – (21,220 more than 2008)
2008☝692,000 – (13,940 more than 2007)

2007👇678,060 – (1,450 less than 2006)
2006☝679,510 – (16,640 more than 2005)
2005👇662,870 – (5,600 less than 2004)
2004☝668,470 – (9,670 more than 2003)
2003☝658,800 – (11,400 more than 2002)
2002
_-_647,400
——————————————————————
Estimated New invasive Breast Cancer Cases: (Women)
——————————————————————
2013☝232,340 (29%) (5,470 more than 2012)
2012👇226,870 (29%) (11,610 less than 2011)
2011☝238,480 (30%) (31,390 more than 2010)
2010☝207,090 (28%) (14,720 more than 2009)
2009☝192,370 (27%) (9,910 more than 2008)
2008☝182,460 (26%) (3,980 more than 2007)

2007👇178,480 (26%) (2007-2008) (34,440 less than 2006)
2006☝212,920 (31%) (1,680 more than 2005)
2005👇211,240 (32%) (4,660 less than 2004)
2004☝215,900 (32%) (4,600 more than 2003)
2003☝211,300 (32%) (7,800 more than 2002)
2002
_-_203,500 (31%)
——————————————————————
Estimated new cases – new cancer cases expected to be diagnosed among African Americans:
——————————————————————
2013☝176,620 (2013-2014)
2011☝168,900 (About) (2011-2012)

2009👇150,090 (About) (2009-2010)
2008☝182,460 (26%)
2007_-_152,900 (About) (2007-2008)

——————————————————————
Estimated new cases of in situ breast cancer expected to occur:
——————————————————————
64,640☝(2013) (1,340 more than 2012)
63,300☝(2012) (5,650 more than 2011)
57,650☝(2011) (3,640 more than 2010)

54,010👇(2010) (8,270 less than 2009)
62,280👇(2009) (5,490 less than 2008)
67,770☝(2008) (5,740 more than 2007-2008)
62,030☝(2007-2008) (50 more than 2006)
61,980☝(2006) (3,490 more than 2005-2006)

58,490👇(2005-2006) (900 less than 2004)
59,390☝(2004) (3,690 more than 2003)
55,700☝(2003) (1,400 more than 2002)
54,300☝(2002)

——————————————————————
Estimated New Cancer Cases – African Americans – Breast
——————————————————————
2013☝27,060 – 33% (2013-2014)
2011☝26,840 – 34% (2011-2012)
2009☝19,540 – 25% (2009-2010)
2007☝19,010 – 27% (2007-2008)

19,240 – 1979-2001 – 29.9% – 2005 (2005-2006)
——————————————————————
Estimated new cases of in situ breast cancer expected to occur = detection of below # of ductal carcinoma in situ (DCIS):
——————————————————————
54,944 (2013)
85% (2003-2012)
88% (2002)

1998-2002 accounted for about 85% of in situ breast cancers diagnosed (2005-2006)
1980-2001 – Incidence rates of DCIS increased more than sevenfold in all age groups, although greatest in women 50 and older (2005-2006)
——————————————————————
LEADING CAUSE OF DEATH
——————————————————————
2013 – breast cancer expected to be most commonly diagnosed cancer in women
——————————————————————
BREAST CANCER – 2nd
——————————————————————
2013 – Breast cancer 2nd most common cause of cancer death among African American women, surpassed only by lung cancer (2009-2012)
(2007)
——————————————————————
2003 – Breast cancer is 2nd among cancer deaths in women

2002-2003: 2nd leading cause of death

2002 – Breast cancer 2nd leading cause of death
————————————-
Breast cancer most common cancer among African American women

34% – (2011-2012)
25% – (2009-2010)
2007
——————————————————————
2011 – New Cases
(2011-2012)

New Cases: Breast cancer most commonly diagnosed cancer among African American women
——————————————————————
BREAST CANCER – AFRICAN AMERICAN WOMEN
——————————————————————
34% – African American women most common cancer (2011-2012)

African American Women Most common cancer (2005-2006)
——————————————————————
2005 – African American women – more likely to die from at any age
——————————————————————
ESTIMATED WOMEN BREAST CANCER DEATHS
——————————————————————
19% – number of cancer deaths breast cancer in women (2007-2012)
——————————————————————
since 1990 – Death rates from breast cancer steadily decreased in women (2009-2010)

since 1990 – death rate from breast cancer in women decreased (2007-2008)
——————————————————————
1.9% – 2000-2009 cancer mortality rate for women of all races combined declined annually (2012-2013)
——————————————————————
1990-2006 – death rate from breast cancer in women decreased (2005-2006)
——————————————————————
2.2% – 1990-2004 cancer mortality rate for women of all races combined decreased annually (2007-2008)

decline larger among younger age groups (2007-2008)
——————————————————————
2.3% – 1990-2002 rate decreased annually – percentage of decline larger among younger age groups (2005-2006)
——————————————————————
2.3% – 1990-2000 breast cancer death rates decreased annually (2005-2006)
——————————————————————
1992-1998 – mortality rates declined significantly

largest decreases in younger women, both white and black (2002)
——————————————————————
1.6% – 1975-1991 – Breast Cancer Death Rates Increased annually (2005-2006)
——————————————————————
0.4% – 1975-1990 – breast cancer death rates increased annually (2005-2006)
——————————————————————
0.4% – 1975-1990 death rate for all races combined increased annually (2005-2008)
——————————————————————
rate for women of all races combined decreased annually (2007-2008)

decline larger among younger age groups (2007-2008)
——————————————————————
BREAST CANCER – OLDER WOMEN
——————————————————————
Older women much more likely to get breast cancer than younger women
——————————————————————
% FEMALE BREAST CANCER DEATH RATES (age)
——————————————————————
97% – 1998-2002 – age 40 and older (2005-2008)
96% – 1996-2000 – age 40 and older (2005-2006)
——————————————————————
WOMEN YOUNGER than 50
——————————————————————
3.0% – under age of 50 – Mortality from breast cancer declined faster for women (annually from 2005-2009) regardless of race/ethnicity (2013)
——————————————————————
2.3% – 1990-2001 Breast Cancer Death Rates decrease

largest decrease in < 50 (2005-2006)
——————————————————————
3.7% – 1991-2000 under 50 breast cancer Death rates decreased (2005-2006)
——————————————————————
3.3% – 1990-2004 – death rates decreased per year among women younger than 50 (2005c-2008)
——————————————————————
2.3% – 1990-2002 Death rates from breast cancer declined average per year in all women combined, with larger decreases in younger (<50 years) women (2006)
——————————————————————
WOMEN 50 and older
——————————————————————
1.2% – 50 and older – decrease in breast cancer death rates smaller in African American than white women (2009-2010)
——————————————————————
2.0% – 50 and older – 1990-2004 – death rates decreased per year among women (2005-2008)
——————————————————————
WHITE WOMEN
——————————————————————
2.1% – 2000-2009 – breast cancer death rates declined per year in white women
——————————————————————
2.6% – 1992-2000 – breast cancer Death rates Whites (2005-2006)
——————————————————————
2.4% – 1990-2004 female breast cancer death rates declined per year in whites (2005-2008)
——————————————————————
early 1980’s – Breast Cancer Death Rates equal – African American / White (2005-2006)
——————————————————————
AFRICAN AMERICAN WOMEN – ALL CANCERS
——————————————————————
1.5% – since 1999 – Death rates among women (African Americans for all cancers combined) per year have been decreasing (2011-2012)
——————————————————————
AFRICAN AMERICAN WOMEN BREAST CANCER DEATHS
——————————————————————
black women more likely to die of breast cancer than white women (2012-2013)
——————————————————————
2005-2006 African American women more likely to die from breast cancer at every age
——————————————————————
41% – 2005-2009 African American women had higher death rate than white women despite lower incidence rate

39% – 2003-2007 – African American women had higher death rate than white women, despite lower incidence rate (2011-2012)

difference accounts for more than one-third (37%) of overall cancer mortality disparity between African American and white women (2011-2012)

37% – 2001-2005 – African American women had higher death rate than white women (2009-2010)

higher breast cancer mortality rate among African American women compared to white women occurs despite lower incidence rate (2009-2010)

difference accounts for more than one-third (37%) of overall cancer mortality disparity between African American and white women (2009-2010)

higher breast cancer mortality rate among African American women compared to white women occurs despite lower incidence rate (2007)

notable, striking divergence in long-term breast cancer mortality rates trends between African American and white women (2005-2008)

36% – by 2004 – death rates higher in African Americans than white women (2007-2008)
37% – by 2002 – death rates higher in African American women than white women (2005-2006)
36% – 2000-2003 – death rates higher in African American women than white women (2007)

difference accounts for one-third of excess cancer mortality experienced by African American women compared to white women (2007)

32% – 2000 – Breast Cancer Death rate higher in African American women even though had lower incidence rates (2005-2006)
——————————————————————
AFRICAN AMERICAN WOMEN – 50 and older
——————————————————————
1.2% – 50 and older – 1992-2012 – per year – women (2011-2012)

2.0% – 50 and older – Breast Cancer Death Rates – per year (2009-2010)
——————————————————————
1.2% – 50 and older – decrease in breast cancer death rates smaller in African American than white women (2009-2010)

1.1% – 50 and older – 1991-2007 – African American women Breast cancer death rates declined annually (2007)

2.0% – 50 and older – 1990-2000 – breast cancer Death rates decreased (2005-2006)
——————————————————————
1990 – 50 and older – Breast Cancer Death Rates Increase predominantly due to
——————————————————————
AFRICAN AMERICAN WOMEN – under 50
——————————————————————
2.0% – 1992-2012 – decrease larger in women under 50 – declined thereafter per year (2011-2012)

1.9% – 1992-2009 – decrease larger in women under 50 – declined thereafter per year (2009-2010)

resulted in growing disparity

3.3% per year – larger decreases in women younger than 50 – Breast Cancer Death Rates (2009-2010)
——————————————————————
1.9% – 1991_-_2007 – decrease larger in women under 50 – African American women Breast cancer death rates declined annually per year
——————————————————————
AFRICAN AMERICAN WOMEN
——————————————————————
2000-2009 – death among females, rate of decline similar

As result, overall racial disparity narrowed
——————————————————————
2000-2009 death rate declined faster among African Americans females rate of decline than whites

1.5% – 2000-2009 African Americans females rate of decline per year (2013-2014)

1.4% – 2000-2009 whites rate of decline per year (2013-2014 )
——————————————————————
1.4% – 2000-2009 – breast cancer death rates declined more slowly per year in African American women
——————————————————————
1990-2002
African American women benefited less than white women from advances (2005-2008)
——————————————————————
1.1% – breast cancer death rates African Americans (2005-2006)
——————————————————————
1.6% – 1995-2004 – female breast cancer death rates declined per year in African Americans (2007-2008)

1.0% – 1990-2002 female breast cancer death rates declined per year – African Americans (2005-2006)
——————————————————————
early 1990s – Death rates among African Americans for all cancers combined have been decreasing (2011-2012)
——————————————————————
breast cancer death rates have declined more slowly in African American women compared to white women, which has resulted in growing disparity (2011-2012)
——————————————————————
gap much smaller among women
racial difference in overall cancer death rates due largely to cancers of breast and colorectum in women

racial disparity has widened for breast cancer in women (2011-2012)
——————————————————————
early 1980s – disparity in breast cancer death rates between African American and white women began in (2007-2008)
——————————————————————
early 1980s – breast cancer death rates for white and African American women approximately equal (2007)
——————————————————————
30% – early 1980’s-2000 – disparity between African American and white Deaths (2005-2006)
——————————————————————
early 1980s – disparity in breast cancer death rates between African American and white women appeared (2005-2006)
——————————————————————
early 1980s – breast cancer death rates for white and African American women

similar (2011-2014)

equal (2009-2010)

early 1980’s – Breast Cancer Death Rates equal – African American / White (2005-2006)
——————————————————————
1.5% – 1975-1992 – Breast cancer death rates among African American women increased annually (2009-2012)

1.6% – 1975-1991 – African American women Breast cancer death rates increased annually (2007)
——————————————————————
1975-2007 – death rates for all cancers combined continued to be substantially higher among African Americans than whites (2011-2012)
——————————————————————
AFRICAN AMERICAN WOMEN BREAST CANCER DEATH RATE RATIOS per 100,000 women
——————————————————————
35.4 – African American – 1997-2001 – Breast Cancer Death Rate Ratios per 100,000 (2005-2006)

26.4 – White – 1997-2001 – Breast Cancer Death Rate Ratios per 100,000 (2005-2006)

1.3 – African American / White Ratio – 1997-2001 – Breast Cancer Death Rate Ratios per 100,000 (2005-2006)
——————————————————————
HISPANIC / LATINA WOMEN
——————————————————————
2.4% – 1995-2004 female breast cancer death rates declined per year in Hispanics / Latinas (2007-2008)
1.8% – 1990-2002 female breast cancer death rates declined per year in Hispanics / Latinas (2005-2006)
1.4% – breast cancer Death rates Hispanics (2005-2006)

1990-2002
women of other racial and ethnic groups benefited less than white women from advances (2005-2008)
——————————————————————
ASIAN AMERICAN / PACIFIC ISLANDER WOMEN
——————————————————————
1995-2004 female breast cancer death rates remained unchanged among Asian Americans/Pacific Islanders (2007-2008)

1.1% – breast cancer Death rates Asian and Pacific Islanders (2005-2006)

1.0% – 1990-2002 female breast cancer death rates declined per year – Asian Americans / Pacific Islanders (2005-2006)
——————————————————————
1990-2002
women of other racial and ethnic groups benefited less than white women from advances (2005-2008)
——————————————————————
AMERICAN INDIAN / ALASKA NATIVE WOMEN
——————————————————————
1995-2004 female breast cancer death rates remained unchanged among American Indians / Alaska Natives (2007-2008)

1990-2002 female breast cancer death rates did not decline in American Indian / Alaska Natives (2005-2006)
——————————————————————
1990-2002
women of other racial and ethnic groups benefited less than white women from advances (2005-2008)
——————————————————————
breast cancer Death rates American Indian and Alaska Native – constant (2005-2006)
——————————————————————
DEATHS – 2007-2008
——————————————————————
40,460 – Deaths – All ages (2007-2008)
23,510 – Deaths – 65 and older (2007-2008)
16,950 – Deaths – Younger than 65 (2007-2008)
31,320 – Deaths – 55 and older (2007-2008)
9,140 – Deaths – Younger than 55 (2007-2008)
37,630 – Deaths – 45 and older (2007-2008)
2,830 – Deaths – Younger than 45 (2007-2008)
——————————————————————
MORTALITY (DEATH) RATES
——————————————————————
31.0 – Black – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)

24.3 – White – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)

14.8 – Hispanic – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)

12.4 – American Indian / Alaskan Native – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)

11.0 – Asian / Pacific Islander – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)
——————————————————————
WHITE WOMEN – MORE LIKELY TO DEVELOP BREAST CANCER
——————————————————————
Combining all age groups, white (non-Hispanic) women more likely to develop breast cancer than black women
——————————————————————
PROBABILITY of DEVELOPING BREAST CANCER in NEXT 10 YEARS (Age)
——————————————————————
20
——————————————————————
20 – 0.05% – 1 in 2,152 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
20 – 0.05% – 1 in 1,985 – 2000-2002 probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
20 – 0.05% – 1 in: 1,837 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
30
——————————————————————
30 – 0.44% – 1 in: 229 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
30 – 0.43% – 1 in: 234 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
30 – 0.40% – 1 in 251 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
40
——————————————————————
40 – 1.46% – 1 in: 68 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
40 – 1.45% – 1 in 69 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
40 – 1.43% – 1 in: 70 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
50
——————————————————————
50 – 2.78% – 1 in 36 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
50 – 2.73% – 1 in: 37 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
50 – 2.51% – 1 in: 40 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
60
——————————————————————
60 – 3.82% – 1 in: 26 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
60 – 3.81% – 1 in 26 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
60 – 3.51% – 1 in: 28 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
70
——————————————————————
70 – 4.31% – 1 in 23 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
70 – 4.14% – 1 in: 24 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
70 – 3.88% – 1 in: 26 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
LIFETIME RISK
——————————————————————
13.2% – 1 in 8 – 2005-2006 Currently, woman living in US has, or, lifetime risk of developing breast cancer
——————————————————————
13.22% – Lifetime risk – 1 in: 8 – 2000-2002 probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
12.28% – Lifetime risk – 1 in: 8 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
AFRICAN AMERICAN LIFE EXPECTANCY
——————————————————————
2007 – life expectancy lower for African Americans than whites among women

(76.5 vs. 80.6 years) (2011-2012)
——————————————————————
DEVELOPING INVASIVE BREAST CANCER
——————————————————————
1 in 8 – 2013 – chance of developing invasive breast cancer during lifetime
——————————————————————
1 in 8 – 12.3% – Currently, woman living in US has lifetime risk of developing breast cancer (2007-2008)
——————————————————————
about 1 in 11 – 1975
——————————————————————
1 in 11 – 1970s – lifetime risk of being diagnosed with breast cancer (2007-2008)
——————————————————————
result of rounding to nearest whole number, small decrease in lifetime risk (from 1 in 7.47 to 1 in 7.56) led to change in lifetime risk from 1 in 7 previously reported in Breast Cancer Facts & Figures 2003-2004 and Cancer Facts & Figures 2005 to current estimate of 1 in 8

Overall, lifetime risk of being diagnosed with breast cancer gradually increased over past 3 decades (2005-2006)
——————————————————————
INVASIVE BREAST CANCER – by age (2007-2008)
——————————————————————
178,480 – All ages
72,520 – 65 and older
105,960 – Younger than 65
124,300 – 55 and older
54,180 – Younger than 55
162,330 – 45 and older
16,150 – Younger than 45
——————————————————————
INVASIVE BREAST CANCER – by # (2007-2008)
——————————————————————
178,480 – All ages
162,330 – 45 and older
124,300 – 55 and older
105,960 – Younger than 65
72,520 – 65 and older
54,180 – Younger than 55
16,150 – Younger than 45
——————————————————————
INVASIVE BREAST CANCER
——————————————————————
0.3% – 1987-2002 – Incidence Trends: increased per year (2005-2006)
————————————-
—————————–
4% (almost) – 1980-1987 – increased (almost +4% a year) Incidence Trends (2005-2006)
——————————————————————
age 40-49
——————————————————————
Since 1987 – age 40-49 – incidence rates of invasive breast cancer have slightly declined (2005-2006)

3.5% – 40-49 (age) – 1980-1987 – incidence rates of invasive breast cancer increased among women per year – Incidence Trends: Invasive Breast Cancer (2005-2006)
——————————————————————
age 50 and older
——————————————————————
Since 1987 – 50 and older – incidence rates of invasive breast cancer have continued to increase among women, though at much slower rate (2005-2006)

4.2% – 50 and older – incidence rates of invasive breast cancer increased among women per year – Incidence Trends: Invasive Breast Cancer (2005-2006)
——————————————————————
Under 40
——————————————————————
Under 40 – remained essentially constant (2005-2006)

Since 1987 – younger than 40 – relatively little change in incidence rates of invasive breast cancer in women (2005-2006)
——————————————————————
Invasive Breast Cancer
——————————————————————
1975-2000 – Invasive Breast Cancer (2005-2006):

4% – 40 and older – increased 1980-1987 then stabilized (2005-2006)
——————————————————————
1992-2002 – overall incidence rates did not change significantly among whites, African Americans, and Hispanics / Latinas (2005-2006)
——————————————————————
1.3% – Hispanics – increased overall (2005-2006)
——————————————————————
0.9% – Whites – increased overall (2005-2006)
——————————————————————
African Americans – stabilized (2005-2006)
——————————————————————
Asian Americans / Pacific Islanders
——————————————————————
2.1% – 1992-2002 – Asian and Pacific Islanders – overall incidence rates increased overall (2005-2006)

1.5% – 1992-2002 – Asian Americans / Pacific Islanders – overall incidence rates increased per year (2005-2006)

trends in invasive female breast cancer incidence rates (2005-2006)
——————————————————————
American Indian / Alaska Natives
——————————————————————
3.7% – American Indian / Alaska Native – decreased overall (2005-2006)

3.5% – 1992-2002 – American Indian / Alaska Natives – overall incidence rates decreased per year (2005-2006)

trends in invasive female breast cancer incidence rates (2005-2006)
——————————————————————
essentially constant – Incidence Trends
——————————————————————
1973-1980 – essentially constant – Incidence Trends (2005-2006)
——————————————————————
African Americans more likely to be diagnosed at later stage of disease when treatment choices are more limited and less effective (2013-2014)
——————————————————————
MEDIAN AGE of DIAGNOSIS
——————————————————————
62 – median age of diagnosis for -white women
——————————————————————
57 – median age of diagnosis for African American women
——————————————————————
DIAGNOSIS at LOCAL STAGE
——————————————————————
61% – breast cancers diagnosed among white women at local stage (2011-2012)
——————————————————————
51% (Only about half) – of breast cancers diagnosed among African American women are local stage (2011-2014)
——————————————————————
MEDIAN AGE AT TIME OF BREAST CANCER DIAGNOSIS
——————————————————————
61 – 2000_-_2004 median age at time of breast cancer diagnosis (2007-2008)
61 – 1998_-_2002 median age at time of breast cancer diagnosis
——————————————————————
61 – means 50% of women who developed breast cancer were 61 or younger (2007-2008)
50% of women who developed breast cancer were age 61 or younger 1998_-_2002
——————————————————————
61 – 50% were older than 61 when diagnosed (2007-2008)

50% were older than age 61 when diagnosed 1998_-_2002
——————————————————————
2005_-_2009 % / age DIAGNOSED with BREAST CANCER
——————————————————————
61 – median age for breast cancer diagnosis

0.0% – under age 20
1.8% – between 20-34
9.9% – between 35-44
22.5% – between 45-54
24.8% – between 55-64
20.2% – between 65-74
15.1% – between 75-84
5.7% – 85+
——————————————————————
2005_-_2009 % / age DIAGNOSED with BREAST CANCER by % (SEER, 2012)
——————————————————————
24.8% – between 55-64
22.5% – between 45-54
20.2% – between 65-74
15.1% – between 75-84
9.9% – between 35-44
5.7% – 85+
1.8% – between 20-34
0.0% – under age 20
——————————————————————
IN SITU BREAST CANCER – by age (2007-2008)
——————————————————————
62,030 – All ages
21,510 – 65 and older
40,520 – Younger than 65
37,110 – 55 and older
24,920 – Younger than 55
54,390 – 45 and older
7,640 – Younger than 45
——————————————————————
IN SITU BREAST CANCER – by # (2007-2008)
——————————————————————
62,030 – All ages
54,390 – 45 and older
40,520 – Younger than 65
37,110 – 55 and older
24,920 – Younger than 55
21,510 – 65 and older
7,640 – Younger than 45
——————————————————————
NEW CASES – IN SITU BREAST CANCER
——————————————————————
increase observed in all age groups, although greatest in women 50 and older (2007-2008)
——————————————————————
Since 2000 – incidence rates of in situ breast cancer leveled off among women 50 and older (2007-2008)
——————————————————————
Since 2000 – incidence rates of in situ breast cancer have continued to increase in younger women (2007-2008)
——————————————————————
80% – 2000-2004 – Most in situ breast cancers are ductal carcinoma (DCIS), which accounted for about 80% of in situ breast cancers diagnosed (2007-2008)
——————————————————————
2000-2004 – Lobular carcinoma in situ (LCIS) less common than DCIS, accounting for about 10% of female in situ breast cancers diagnosed (2007-2008)

Similar to DCIS, overall incidence rate of LCIS increased more rapidly than incidence of invasive breast cancer (2007-2008)

increase limited to women older than age 40 and largely to postmenopausal women (2007-2008)
——————————————————————
1998-2002 accounting for female in situ breast cancers diagnosed (2005-2006):

12% – Lobular carcinoma in situ (LCIS) less common than DCIS

Similar to DCIS, overall incidence rate of LCIS increased more rapidly than incidence of invasive breast cancer

increase limited to women older than 40 and largely to postmenopausal women
——————————————————————
1980s and 1990s – Incidence rates of in situ breast cancer increased rapidly (2007-2008)
——————————————————————
New cancer cases in women expected to be newly diagnosed among African Americans:
——————————————————————
2013 – 82,080 (About)
——————————————————————
19% – breast cancer in women (2007-2008)
——————————————————————
2002 – Breast cancer ranks 2nd among cancer deaths in women
——————————————————————
2002-2003: 2nd leading cause of death
——————————————————————
African American women expected to die from cancer:
——————————————————————
African Americans have the highest death rate and shortest survival of any racial and ethnic group in the US for most cancers
(2007-2014)
African Americans have the highest mortality rate of any racial and ethnic group in the US for most cancers
(2005-2006)
——————————————————————
higher death rate in African
American women compared to white women occurs despite lower cancer incidence rate (2013-2014)
——————————————————————
African American women have higher death rates overall and for breast and several other cancer sites (2013-2014)
——————————————————————
15% – 2009 – death rate for all cancers combined continued to be higher in African American women than in white women (2013-2014)
——————————————————————
racial difference in overall cancer death rates is due largely to cancers of the breast and colorectum in women (2013-2014)
——————————————————————
overall racial disparity in cancer death rates decreasing (2013-2014)
——————————————————————
16% – 2007 – death rate for all cancers combined higher in African American women than white women (2011-2012)
——————————————————————
37% – by 2002 – death rates higher in African Americans than white women (2005-2006)
——————————————————————
since early 1990s – death rates among African Americans for all cancers combined have been decreasing (2013-2014)
——————————————————————
30% – early 1980’s–2000 – Deaths disparity between African American and white (2005–2006)
——————————————————————
1975-2009 – Despite declines, death rates for all cancers combined continued to be higher among African Americans than whites (2013-2014)
——————————————————————
1992-2014 – Breast cancer death rates among African American women declined
——————————————————————
1.4% per year – 2000-2009 – breast cancer death rates declined more slowly in African American women
——————————————————————
2.1% per year – 2000-2009 – breast cancer death rates declined white women
——————————————————————
early 1980s – breast cancer death rates for white and African American women similar
——————————————————————
1975-1992 – Breast cancer death rates among African American women increased
resulted in growing disparity
——————————————————————
through 1998 – breast cancer incidence rates among young white women continued to increase more slowly (2002)
——————————————————————
1980s – 4.5% per year increase (2002)
——————————————————————
As result, overall racial disparity narrowed (2013-2014)
——————————————————————
1992-1998 – mortality rates declined significantly – largest decreases in younger women, both white and black (2002)
——————————————————————
1992-1998 – Incidence and Mortality Rates* by Site, Race, and Ethnicity (2002)
——————————————————————
Incidence
——————————————————————
115.5 – White
101.5 – Black
78.1 – Asian / Pacific Islander
50.5 – American Indian / Alaskan Native
68.5 – Hispanic
——————————————————————
Mortality
——————————————————————
31.0 – Black
24.3 – White
14.8 – Hispanic
12.4 – American Indian / Alaskan Native
11.0 – Asian / Pacific Islander
——————————————————————
Cancer Facts & Figures for African Americans 2005-2006
——————————————————————
1995-2000 (2001) – Diagnosed
Female breast (2005-2006)
:
——————————————————————
Localized
——————————————————————
64% – White (2005-2006)
53% – African American (2005-2006)
——————————————————————
Regional
——————————————————————
35% – African American (2005-2006)
28% – White (2005-2006)
——————————————————————
Distant
——————————————————————
9% – African American (2005-2006)
5% – White (2005-2006)
——————————————————————
Unstaged
——————————————————————
3% – African American (2005-2006)
2% – White (2005-2006)
——————————————————————
2005-2006 – Cancer Incidence Rates Ratios per 100,000 (1975-2001)
——————————————————————
1997-2001 – Breast (2005-2006)
143.2 – White (2005-2006)
118.6 – African American (2005-2006)
0.8 – African American / White Ratio (2005-2006)
——————————————————————
2005-2006 – Cancer Death Rate Ratios per 100,000
——————————————————————
1997-2001 – Breast (2005-2006)
35.4 – African American (2005-2006)
26.4 – White (2005-2006)
1.3 – African American / White Ratio (2005-2006)
——————————————————————
Most common cancer among African American Women (2005-2006)
——————————————————————
17% lower incidence rate in African American than White (2005-2006)
——————————————————————
under 40 – higher incidence rate in African American than White (2005-2006)
——————————————————————
25 years incidence:
——————————————————————
1999-2001 – leveling off (2005-2006)
1986-1999 – less rapid increase (2005-2006)
1978-1986 – rapid increase (2005-2006)
1975-1978 – stable (2005-2006)
——————————————————————
Breast Cancer Death Rates Increased (2005-2006):
——————————————————————
1975-1991 – + 1.6% – annually (2005-2006)
——————————————————————
1991 – decided annually: particularly in women younger than 50 (2005-2006)
——————————————————————
Breast Cancer Death Rates (2005-2006):
——————————————————————
early 1980’s – equal – African American / White (2005-2006)
——————————————————————
2000 – 32% – higher African American (2005-2006)
——————————————————————
Death rate higher in African American even though had lower incidence rates (2005-2006)
——————————————————————
Rate per 100,000
——————————————————————
White
African American
Asian or Pacific Islander
Hispanic
American Indian or Alaska Native
——————————————————————
1996-2000 – Incidences:

140.8 – White
121.7 – African American
97.2 – Asian or Pacific Islander
89.8 – Hispanic
58 – American Indian or Alaska Native
——————————————————————
1996-2000 – Deaths

35.9 – African American
27.2 – White
17.9 – Hispanic
14.9 – American Indian or Alaska Native
12.5 – Asian or Pacific Islander
——————————————————————
Estimated New In Situ Cases:
——————————————————————
2003_-_100 – < 30
2005 – 1,600 – Under 40
2003 – 2,100 – 30-39
2005 – 56,890 – 40 and older
2005 – 13,760 – Under 50
2003 -12,600 – 40-49
2005 – 44,730 – 50 and older
2005 – 37,040 – Under 65
2003 – 15,700 – 50-59
2005 – 21,450 – 65 and older
2003 – 11,500 – 60-69
2003 – 10,100 – 70-79
2003 – 3,500 – 80 +
2005 – 58,490 – All ages
TOTAL
2003 – 55,700
——————————————————————
2003_-_100 – 0.2%
2003 – 2,100 – 3.8%
2003 – 12,600 – 22.6%
2003 – 15,700 – 28.2%
2003 – 11,500 – 20.6%
2003 – 10,100 – 18.1%
2003 – 3,500 – 16.3
TOTAL
2003 – 100.0%
——————————————————————
Estimated New Invasive Cases:
——————————————————————
2003 – 1,000 – < 30
2005 – 9,510 – Under 40
2003 – 10,500 – 30-39
2005_-_201,730 – 40 and older
2005 – 45,780 – Under 50
2003 – 35,500 – 40-49
2005_-_165,460 – 50 and older
2005_-_123,070 – Under 65
2003 – 48,700 – 50-59
2005 – 88,170 – 65 and older
2003 – 43,100 – 60-69
2003 – 45,600 – 70-79
2003 – 27,000 – 80 +
2005_-_211,240 – All ages
TOTAL
2003 – 55,700 –
——————————————————————
2003 – 1,000 – 0.5%
2003 – 10,500 – 5.0%
2003 – 35,500 – 16.8%
2003 – 48,700 – 23.0%
2003 – 43,100 – 20.4%
2003 – 45,600 – 21.6%
2003 – 27,000 – 12.8%
TOTAL
2003 – 100.00%
——————————————————————
Deaths:
——————————————————————
2003_-_100 – < 30
2005 – 1,110 – Under 40
2003 – 1,300 – 30-39
2005 – 39,300 – 40 and older
2005 – 5,590 – Under 50
2003 – 4,300 – 40-49
2005 – 34,820 – 50 and older
2005 – 17,470 – Under 65
2003 – 7,000 – 50-59
2005 – 22,940 – 65 and older
2003 – 7,400 – 60-69
2003 – 9,500 – 70-79
2003 – 10,100 – 80 +
2005 – 40,410 – All ages
TOTAL
2003 – 39,800
——————————————————————
2003_-_100 – 0.3%
2003 – 1,300 – 3.3%
2003 – 4,300 – 10.8%
2003 – 7,000 – 17.6 %
2003 – 7,400 – 18.6%
2003 – 9,500 – 23.9%
2003 – 10,100 – 25.4%
TOTAL
2003 – 100.0
——————————————————————
1990 – Increase since predominantly due to women 50 and older
——————————————————————
1998-2002 accounting for female in situ breast cancers diagnosed (2005-2006):
——————————————————————
12% – Lobular carcinoma in situ (LCIS) less common than DCIS

Similar to DCIS, overall incidence rate of LCIS increased more rapidly than incidence of invasive breast cancer

increase limited to women older than 40 and largely to postmenopausal women
——————————————————————
1990-2001 (2005-2006):
——————————————————————
2.3% – decrease
largest decrease in < 50
——————————————————————
1998-2002 women aged 40 and older (2005-2006):
——————————————————————
95% – new cases
97% – breast cancer deaths
——————————————————————
1996-2000 Women 40 and older (2005-2006):
——————————————————————
94% – New Cases
96% – Deaths
——————————————————————
0.3% per year – Incidence rates declined slightly among white females (2013-2014)
——————————————————————
1996-2002 (2005-2006):
——————————————————————
20-24 – 1.3 per 100,000 lowest incidence rate – 1998-2002 (2005-2006)

20-24 – 1.4 per 100,000 lowest incidence rate – 1996-2000 (2005-2006)
——————————————————————
75-79 – 496.6 per 100,000 highest incidence rate – 1998-2002 (2005-2006)

75-79 – 499.0 per 100,000 highest incidence rate – 1996-2000 (2005-2006)
——————————————————————
2005-2006
•
White women higher incidence of breast cancer than African American women after 35

African American women slightly higher incidence rate before 35

African American women more likely to die from breast cancer at every age
——————————————————————
2005

White – higher incidence rate than African American women after 40

African American – slightly higher incidence rate before 40

African American women – more likely to die from at any age
——————————————————————
2005-2006 incidence and death rates from breast cancer lower among women of other racial and ethnic groups than white and African American women
——————————————————————
2000-2009 – stable among African American females (2013-2014)
——————————————————————
1975-1980 essentially constant (2005-2006)
1980-1987 + almost 4% per year (2005-2006)
1987-2002 + 0.3% per year (2005-2006)
•
Incidence Trends
Invasive Breast Cancer (2005-2006)
:

1973-1980 – essentially constant (2005-2006)
1980-1987 – + almost 4% year (2005-2006)
1987-2000 – 0.4% year (2005-2006)
——————————————————————
1980-1987 incidence rates of invasive breast cancer increased among women (2005-2006):
——————————————————————
40-49 (3.5% per year) (2005-2006)
50 and older (4.2% per year) (2005-2006)
Since 1987
50 and older – rates have continued to increase among women , though at much slower rate (2005-2006)

40-49 -rates have slightly declined (2005-2006)

younger than 40 – relatively little change in incidence rates of invasive breast cancer in women (2005-2006)

1975-2000 – Invasive Breast Cancer (2005-2006):

4% – 40 and older increased 1980 – 1987 then stabilized (2005-2006)

Under 40 – remained essentially constant (2005-2006)
——————————————————————
2005-2006 trends in invasive female breast cancer incidence rates:
——————————————————————
1992-2002
(1.5% per year) – overall incidence rates increased in Asian Americans / Pacific Islanders (2005-2006)

(3.5% per year) – decreased in American Indian/Alaska Natives (2005-2006)

did not change significantly among whites, African Americans, and Hispanics/Latinas (2005-2006)

1992-2000 – Invasive (2005-2006):

2.1% – Asian and Pacific Islanders – increased overall (2005-2006)
1.3% – Hispanics – increased overall (2005-2006)
0.9% – Whites – increased overall (2005-2006)
3.7% – American Indian and Alaska Native – decreased overall (2005-2006)
——————————————————————
African Americans – stabilized (2005-2006)
——————————————————————
since 1990 – death rate from breast cancer in women decreased (2005-2006)
——————————————————————
1975-1990
0.4% – death rate for all races combined increased annually (2005-2006)
•
1990-2002
2.3% – rate decreased annually
percentage of decline larger among younger age groups (2005-2006)

1990-2002
3.3% – death rates decreased per year among women younger than 50 (2005-2006)

2.0% – per year among women 50 and older (2005-2006)

African American women and women of other racial and ethnic groups have benefited less than white women from advances (2005-2006)

1990-2002 female breast cancer death rates declined (2005-2006):

2.4% – per year – whites (2005-2006)
1.8% – per year – Hispanics/Latinas (2005-2006)
1.0% – per year – African Americans and Asian Americans/Pacific Islanders (2005-2006)

did not decline in American Indian/ Alaska Natives (2005-2006)
——————————————————————
life expectancy lower for African Americans than whites among women (77.2 vs. 80.9 years) (2013-2014)
——————————————————————
As result, overall racial disparity narrowed (2013-2014)
——————————————————————
striking divergence in long-term mortality trends between African American and white females (2005-2006)
——————————————————————
early 1980s – disparity in breast cancer death rates between African American and white women appeared (2005-2006)
——————————————————————
1975-1990 – Death (2005-2006):
0.4% – increased annually (2005-2006)
——————————————————————
1990-2000
2.3% – decreased annually (2005-2006)
——————————————————————
1991-2000
3.7% – under 50 decreased (2005-2006)
——————————————————————
1990-2000
2.0% – 50 and older decreased (2005-2006)
——————————————————————
1992-2000 – Death (2005-2006):
——————————————————————
2.6% – Whites (2005-2006)
1.4% – Hispanics (2005-2006)
1.1% – African Americans (2005-2006)
1.1% – Asian and Pacific Islanders (2005-2006)
American Indian and Alaska Native – constant (2005-2006)
——————————————————————
Probability of developing Breast Cancer in next 10 years:
——————————————————————
Age
——————————————————————
20 – 0.05% – 1 in 2,152 (2005-2006)
20 – 0.05% – 1 in 1,985 – 2000-2002 (2005-2006)†
——————————————————————
30 – 0.40% – 1 in 251 (2005-2006)
30 – 0.44% – 1 in: 229 – 2000-2002 (2005-2006)†
——————————————————————
40 – 1.45% – 1 in 69 (2005-2006)
40 – 1.46% – 1 in: 68 – 2000-2002 (2005-2006)†
——————————————————————
50 – 2.78% – 1 in 36 (2005-2006)
50 – 2.73% – 1 in: 37 – 2000-2002 (2005-2006)†
——————————————————————
60 – 3.81% – 1 in 26 (2005-2006)
60 – 3.82% – 1 in: 26 – 2000-2002 (2005-2006)†
——————————————————————
70 – 4.31% – 1 in 23 (2005-2006)
70 – 4.14% – 1 in: 24 – 2000-2002 (2005-2006)†
——————————————————————
Lifetime Probability (%) of Developing or Dying from Invasive Cancers by Race and Sex
——————————————————————
Developing

12.73 (1 in 8) – White (%) 2007-2009 (2013-2014)

10.87 (1 in 9) – African American (%) 2007-2009 (2013-2014)

Dying

3.25 (1 in 31) – African American (%) 2007-2009 (2013-2014)

2.73 (1 in 37) – White (%) 2007-2009 (2013-2014)

2005-2006 Currently, woman living in US has 13.2%, or 1 in 8, lifetime risk of developing breast cancer (2013-2014)

result of rounding to nearest whole number, small decrease in lifetime risk (from 1 in 7.47 to 1 in 7.56) led to change in lifetime risk from 1 in 7 previously reported in Breast Cancer Facts & Figures 2003-2004 and Cancer Facts & Figures 2005 to current estimate of 1 in 8

2005-2006: Overall, lifetime risk of being diagnosed with breast cancer gradually increased over past 3 decades (2013-2014)
——————————————————————
13.22% – Lifetime risk – 1 in: 8
Comparison of Cancer Incidence Rates between African Americans and Whites
——————————————————————
123.2 – White Rate* 2005-2009 (2013-2014)
121.7 – White Rate* 2003-2007 (2011-2012)
130.6 – White Rate* 2001-2005 +
——————————————————————
118.1 – African American Rate* 2005-2009 (2013-2014)
114.7 – African American Rate* 2003-2007 (2011-2012)
117.6 – African American Rate* 2001-2005 +
——————————————————————
-5.1 – Difference† 2005-2009 (2013-2014)
-7.0 – Absolute Difference† 2003-2007 (2011-2012)
-13.1 – Absolute Difference† 2001-2005 +
——————————————————————
0.96 – Rate Ratio‡ 2005-2009 (2013-2014)
0.94 – Rate Ratio‡ 2003-2007 (2011-2012)
0.90 – Rate Ratio‡ 2001-2005 +

*Rates per 100,000 age adjusted to 2000 US standard population

†Difference is rate in African Americans minus rate in whites

†Absolute difference is rate in African Americans minus rate in whites

‡Rate ratio is unrounded rate in African Americans divided by unrounded rate in whites

‡Rate ratio is rate in African Americans divided by rate in whites based on 2 decimal places

+ Source: Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries 2000-2005, Division of Cancer Control and Population Sciences, National Cancer Institute, 2008
——————————————————————
Comparison of Cancer Death Rates between African Americans and Whites
——————————————————————
31.6 – African American Rate* 2005-2009
32.4 – African American Rate* 2003-2007 (2011-2012)
33.5 – African American Rate* 2001-2005 +
——————————————————————
22.4 – White Rate* 2005-2009
23.4 – White Rate* 2003-2007 (2011-2012)
24.4 – White Rate* 2001-2005 +
——————————————————————
9.2 – Difference† 2005-2009
9.0 – Absolute Difference† 2003-2007 (2011-2012)
9.1 – Absolute Difference† 2001-2005 +
——————————————————————
1.41 – Rate Ratio‡ 2005-2009
1.39 – Rate Ratio‡ 2003-2007 (2011-2012)
1.37 – Rate Ratio‡ 2001-2005 +

*Rates per 100,000 and age adjusted to 2000 US standard population

†Difference is rate in African Americans minus rate in whites

†Absolute difference is rate in African Americans minus rate in whites

‡Rate ratio is unrounded rate in African Americans divided by unrounded rate in whites

‡Rate ratio is rate in African Americans divided by rate in whites based on 2 decimal places

+ Source: Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries 2000-2005, Division of Cancer Control and Population Sciences, National Cancer Institute, 2008
——————————————————————
Stage Distribution for Selected Cancers in African Americans and Whites

Stage Distribution African Americans and Whites
——————————————————————
Localized
——————————————————————
61% – White 2002-2008
61% – White 1999-2006
62% – White 1996-2004 +
——————————————————————
51% – African American 2002-2008
51% – African American 1999-2006
51% – African American 1996-2004 +
——————————————————————
Regional

38% – African American 2002-2008
39% – African American 1999-2006
37% – African American 1996-2004 +
——————————————————————
32% – White 2002-2008
32% – White 1999-2006
31% – White 1996-2004 +
——————————————————————
Distant
——————————————————————
8% – African American 2002-2008
8% – African American 1999-2006
10% – African American 1996-2004 +
——————————————————————
5% – White 2002-2008
5% – White 1999-2006
6% – White 1996-2004 +
——————————————————————
Unstaged
——————————————————————
3% – African American 2002-2008
3% – African American 1999-2006
3% – African American 1996-2004 +
——————————————————————
2% – White 2002-2008
2% – White 1999-2006
2% – White 1996-2004 +
——————————————————————
+ Source:
Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1973-2005, Division of Cancer Control and Population Sciences, National Cancer Institute, 2008
——————————————————————
Probability of Developing Invasive Cancers Over Selected Age Intervals among African Americans by Sex +

Probability of Developing Invasive Cancers:
——————————————————————
Birth to 39 (%):
——————————————————————
0.53 (1 in 189) 2003-2005 * +
0.44 (1 in 229) 1998–2000 (2004)
0.44 (1 in 228) 1997–1999 (2003)
0.44 (1 in 229) 1996–1997 (2002)
——————————————————————
40 to 59(%):
——————————————————————
3.56 (1 in 28) – 40 to 59(%) 2003-2005 * +
4.14 (1 in 24) 1998–2000 (2004)
4.17 (1 in 24) 1997–1999 (2003)
4.17 (1 in 24) 1996–1997 (2002)

2.96 (1 in 34) – 60 to 69 (%) 2003-2005 * +
——————————————————————
60 to 79 (%):
——————————————————————
7.53 (1 in 13) 1998–2000 (2004)
7.14 (1 in 14) 1997–1999 (2003)
7.14 (1 in 14) 1996–1997 (2002)

5.44 (1 in 18) – 70 and Older (%) 2003-2005 * +
——————————————————————
Birth to Death (%)
——————————————————————
9.91 (1 in 10) – Birth to Death (%) 2003-2005 * +
13.36 (1 in 7) 1998–2000 (2004)
13.3 (1 in 8) 1997–1999 (2003)
12.5 (1 in 8) 1996–1997 (2002)

*For people free of cancer at beginning of age interval

+ Source:
DevCan:
Probability of Developing or Dying of Cancer Software, Version 6.3.0. Statistical Research and Applications Branch, National Cancer Institute, 2008
——————————————————————
2005-2006 Currently, woman living in US has 13.2%, or 1 in 8, lifetime risk of developing breast cancer (2013-2014)

result of rounding to nearest whole number, small decrease in lifetime risk (from 1 in 7.47 to 1 in 7.56) led to change in lifetime risk from 1 in 7 previously reported in Breast Cancer Facts & Figures 2003-2004 and Cancer Facts & Figures 2005 to current estimate of 1 in 8
——————————————————————
2005-2006: Overall, lifetime risk of being diagnosed with breast cancer gradually increased over past 3 decades (2013-2014)
——————————————————————
5-YEAR SURVIVAL RATE – ALL
——————————————————————
Survival after diagnosis of breast cancer continues to decline after 5 years (2009-2010)

Survival after diagnosis of breast cancer continues to decline beyond 5 years (2006)
——————————————————————
5-YEAR RELATIVE SURVIVAL LOWER
——————————————————————
5-year relative survival lower among women with more advanced stage at diagnosis (2007-2008)

5-year relative survival lower among women with more advanced stage of disease at diagnosis (2005-2006)
——————————————————————
2005-2006 African American women with breast cancer less likely than white women to survive 5 years:
——————————————————————
90% – white
76% – African American
——————————————————————
Likely to survive 5 years (2005-2006):
——————————————————————
88% – White
74% – African American
——————————————————————
5-YEAR SURVIVAL RATE – ALL STAGES – COMBINED
——————————————————————
89% – survival rate at 5 years for all stages combined (2009-2010)
——————————————————————
88% – all stages combined – 5 year
——————————————————————
77% – all stages combined – 10 year
——————————————————————
5-YEAR RELATIVE SURVIVAL RATE for ALL CANCERS COMBINED
——————————————————————
63% – 2004
62% – 2002-2003
——————————————————————
5-year Relative Survival Rates* for Cancers by Race and Stage

Five-year Relative Survival Rates* for Cancers by Race and Stage at Diagnosis

Five-Year Relative Survival Rates

5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975–2001 (2004)
——————————————————————
Localized
——————————————————————
99% – White 2002-2008 (2013-2014)
61% – White 1999-2006 (2011-2012)
99% – White 1996-2004 +
98% – White 1995–2000 (2005–2006)
——————————————————————
93% – African American 2002-2008 (2013-2014)
51% – African American 1999-2006 (2011-2012)
93% – African American 1996-2004 +
91% – African American 1995–2000 (2005–2006)
——————————————————————
Regional
——————————————————————
85% – White 2002-2008 (2013-2014)
32% – White 1999-2006 (2011-2012)
85% – White 1996-2004 +
82% – White 1995–2000 (2005–2006)
——————————————————————
73% – African American 2002-2008 (2013-2014)
39% – African American 1999-2006 (2011-2012)
72% – African American 1996-2004 +
68% – African American 1995–2000 (2005–2006)
——————————————————————
Distant
——————————————————————
25% – White 2002-2008 (2013-2014)
5% – White 1999-2006 (2011-2012)
29% – White 1996-2004 +
27% – White 1995–2000 (2005–2006)
——————————————————————
15% – African American 2002-2008 (2013-2014)
8% – African American 1999-2006 (2011-2012)
17% – African American 1996-2004 +
15% – African American 1995–2000 (2005–2006)
——————————————————————
All Stages
——————————————————————
90% – White 2002-2008 (2013-2014)
2% – White 1999-2006 (2011-2012)
90% – White 1996-2004 +
56% – White 1995–2000
(2005–2006)
——————————————————————
78% – African American 2002-2008 (2013-2014)
3% – African American 1999-2006 (2011-2012)
77% – African American 1996-2004 +
50% – African American 1995–2000 (2005-2006)
——————————————————————
*Survival rates based on patients diagnosed 2002-2008 followed through 2009

*Survival rates based on patients diagnosed 1999-2006 followed through 2007

Survival rates based on patients diagnosed 1996 – 2004 followed through 2005 +

Local:
invasive cancer confined entirely to organ of origin

Regional:

malignant cancer either

1) extended beyond limits of organ of origin directly into surrounding organs or tissues

2) involves regional lymph nodes by way of lymphatic system

3) both regional extension and involvement of regional lymph nodes

Distant:

malignant cancer spread to parts of body remote from primary tumor either by direct extension or by discontinuous metastasis to distant organs, tissues, or via lymphatic system to distant lymph nodes

+ Source:
Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1973-2005, Division of Cancer Control and Population Sciences, National Cancer Institute, 2008
——————————————————————
Considering all races, 5-year relative survival:

98% – localized disease
81% – regional disease
26% – distant-stage disease

Larger tumor size at diagnosis associated with decreased survival
among women of all races with regional disease, 5-year relative survival:

92% – tumors less than or equal to 2.0 cm
77% – tumors 2.1-5.0 cm
65% – tumors greater than 5.0 cm
——————————————————————
OVERALL 5-YEAR CANCER SURVIVAL RATE (2005-2006)
——————————————————————
55% – 1995-2000 (2005-2006)
27% – 1960-1963 (2005-2006)
——————————————————————
5-YEAR RELATIVE SURVIVAL RATES
——————————————————————
89% – 5 year relative survival rates for women diagnosed with breast cancer after diagnosis (2007-2008)
88% – 5 year relative survival rates for women diagnosed with breast cancer after diagnosis (2005-2006)
87% – 5 year Breast Cancer Survival Rates after Diagnosis (2005-2006)
——————————————————————
age 75 + – 5 year relative survival rate among women diagnosed with breast cancer
——————————————————————
88% – 75 and older (2005-2006)
86% – 75 and over (2005-2006)
——————————————————————
age 65 + – 5 year relative survival rate among women diagnosed with breast cancer
——————————————————————
89% – 65-74 (2005-2006)
88% – 65 and over (2005-2006)
——————————————————————
5-year relative survival rate among women diagnosed with breast cancer
——————————————————————
88% – 55-64 (2005-2006)
89% – 40-74 (2005-2006)
87% – 45-54 (2005-2006)
83% – 45 (less than) (2005-2006)
——————————————————————
40 and older – 5-year relative survival rate
——————————————————————
89% – 40 and older – 5-year relative survival rate slightly lower among women diagnosed with breast cancer (2007-2008)
——————————————————————
younger than 40 – 5-year relative survival rate
——————————————————————
82% – before 40 – slightly lower among women diagnosed with breast cancer (2007-2008)
——————————————————————
82% – younger than 40 – slightly lower among women diagnosed with breast cancer before age 40 – may be due to tumors in age group being more aggressive (2005-2006)
——————————————————————
All – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
86% – 1992-1997 (2002) – 1974-1997
78% – 1983-1985 (2002) – 1974-1997
75% – 1974-1976 (2002) – 1974-1997
——————————————————————
WHITE WOMEN
——————————————————————
69% – white women (2013-2014)
——————————————————————
62% – white women (2007)
——————————————————————
90% – 1999-2006 white women (2011-2012)
——————————————————————
90% – 1996-2004 white women – 5-year relative survival rate for breast cancer diagnosed (2009-2010)
——————————————————————
90% – white women with breast cancer to survive 5 years (2007-2008)
——————————————————————
5-year survival greater among white women (2007)
——————————————————————
90% – 2002-2008 – overall 5-year relative survival rate for breast cancer diagnosed among white women
——————————————————————
88% – White women – Likely to survive 5 years (2005-2006)
——————————————————————
81% – White women – 5 year survivors: relative 5 year survival rate (2005-2006)
——————————————————————
62% – 1996-2004 – white women – 5-year relative survival rate for breast cancer diagnosed (2009-2010)
——————————————————————
90% – 1996-2002 – whites (2007) – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
——————————————————————
90% – 1996-2002 – White – 5-Year Relative Survival – Breast 2007 (2007-2008) +
——————————————————————
89% – 1995-2000 – White – 5-year Relative Survival (1995-2000 (2001) Diagnosis) SEER 1975-2001 (2004) (2005-2006)
——————————————————————
87% – 1992-1997 – White – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
——————————————————————
79% – 1983-1985 – White – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
——————————————————————
75% – 1974-1976 – White – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
——————————————————————
AFRICAN AMERICAN WOMEN
——————————————————————
78% – black women still living 5 years after getting disease (SEER, 2012)
——————————————————————
78% – 1999-2006 – 5-year relative survival rate for breast cancer diagnosed among African American women Survival and Stage at Distribution (2011-2012)
——————————————————————
76% – African American – 5 year survivors relative 5 year survival rate (2005-2006)
——————————————————————
74% – African American – Likely to survive 5 years (2005-2006)
——————————————————————
60% – African Americans – continue to have lower 5-year survival than whites overall and for each stage of diagnosis for most cancer sites (2013-2014)

African Americans continue to be less likely than whites to survive 5 years at each stage of diagnosis for most cancer sites (2009-2010)

Within each stage, 5-year survival also lower among African American women (2009-2010)

78% – 2002-2008 – overall 5-year relative survival rate for breast cancer diagnosed among African American women

77% – African American women with breast cancer less likely than white women to survive 5 years (2007-2008)
76% – African American women with breast cancer less likely than white women to survive 5 years 2005-2006

60% – 2002-2008 – overall 5-year relative survival rate among African Americans improved (2013-2014)

59% – 1999-2006 – African Americans continue to be less likely than whites to survive 5 years at each stage of diagnosis for most cancer sites (2011-2012)

58% – 1996-2004 – overall 5-year relative survival rate among African Americans improved (2009-2010)

77% – 1996-2002 – 5-Year Relative Survival – Breast – African American 2007 (2007-2008) +
77% – 1996-2002 – African American women (2007) – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)

72% – 1992-1997 – Black – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)

63% – 1983-1985 – Black – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)

63% – 1974-1976 – Black – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)

27% – 1960-1963 – overall 5-year relative survival rate among African Americans improved (2009-2014)
——————————————————————
1996-2002 – 5-Year Relative Survival – Breast 2007 – (Based on cancer patients diagnosed 1996-2002 followed through 2003) (2007-2008) +

(Source: Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1975-2003, Division of Cancer Control and Population Sciences, National Cancer Institute, 2006) (2007-2008)
——————————————————————
relative survival rates for women diagnosed with breast cancer (2005-2006):
•
88% – 5 years after diagnosis (2005-2006)
80% – 10 years (2005-2006)
71% – 15 years (2005-2006)
63% – 20 years (2005-2006)
•
Breast Cancer Survival Rates after Diagnosis:
•
87% – 5 years (2005-2006)
77% – 10 years (2005-2006)
63% – 15 years (2005-2006)
52% – 20 years (2005-2006)
——————————————————————
2005-2006 – 5-year relative survival rate slightly lower among women diagnosed with breast cancer before age 40
•
may be due to tumors in age group being more aggressive and less responsive to hormonal therapy:
•
82% – younger than 40 (2005-2006)
89% – 40 – 74 (2005-2006)
88% – 75 and older (2005-2006)
•
5 year relative survival rate (2005-2006):
•
83% – < 45
87% – 45 – 54
88% – 55 – 64
89% – 65 – 74
88% – 65 and over
86% – 75 and over
——————————————————————
5 year survivors
relative 5 year survival rate (2005-2006)
:
•
81% – White
76% – African American
——————————————————————
10 year survivors after diagnosis
relative 5 year survival rate (2005-2006)
:
——————————————————————
87% – White
85% – African American
——————————————————————
LOCALIZED CANCER INCIDENCE RATES RATIOS per 100,000 (1975-2001) – 1995-2000 (2001) – Diagnosed Female breast (2005-2006): Localized – Of all breast cancers diagnosed 2005-2006
——————————————————————
143.2 – White
118.6 – African American

0.8 – African American / White Ratio
——————————————————————
2005-2006
1995-2000 – 5-year Relative Survival (1995-2000 (2001) Diagnosis) SEER 1975-2001 (2004)
89% – White (2005-2006)
75% – African American (2005-2006)
——————————————————————
2005-2006
1995-2000 – 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004)
Female breast
——————————————————————
Localized
——————————————————————
98% – White (2005-2006)
91% – African American (2005-2006)
——————————————————————
Regional
——————————————————————
82% – White (2005-2006)
68% – African American (2005-2006)
——————————————————————
Distant
——————————————————————
27% – White (2005-2006)
15% – African American (2005-2006)
——————————————————————
Unstaged
——————————————————————
56% – White (2005-2006)
50% – African American (2005-2006)
——————————————————————
LOCALIZED 5-YEAR RELATIVE SURVIVAL RATES (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)
——————————————————————
98% – 1995-2000 – White
91% – 1995-2000 – African American
——————————————————————
LOCALIZED
——————————————————————
98% – 2010 – 5-year relative survival for localized breast cancer (malignant cancer that has not spread to lymph nodes or other locations outside breast) has increased (2009-2010)

98% – localized disease: 5-year relative survival – Considering all races (2007-2008)

98% – 2006 – 5-year relative survival for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased

98% – localized disease – 2005-2006 5-year relative survival lower among women with more advanced stage of disease at diagnosis: Considering all races

98% – 2005 – 5 year relative survival for localized

97% – 2004 – 5-year relative survival for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased

96% – 2002 – 5-year relative survival for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased

99% – 1996-2002 White – localized (2007-2008) *

94% – 1996-2002 African American – localized (2007-2008) *

80% – 1950s – 5-year relative survival for localized breast cancer (malignant cancer that has not spread to lymph nodes or other locations outside breast) has increased (2009-2010)

80% – 1950s – 5-year relative survival for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased (2006)

72% – 1940s – 5-year relative survival rate for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased (2002)
——————————————————————
5-year relative survival rate for breast cancer diagnosed at local stage
——————————————————————
77% – 1996-2004 – African American women – 5-year relative survival rate for breast cancer diagnosed at local stage (2009-2010)
——————————————————————
LOCALIZED
——————————————————————
62% – 1996-2002 White – Localized – Stage Distribution – Female breast (2007-2008)

64% – White – Localized (2005–2006)

64% – 1995-2000 (2001) – White: Diagnosed Female breast (2005-2006): Localized – Of all breast cancers diagnosed

5% – 1995-2000 (2001) – White: Diagnosed Female breast (2005-2006): Localized – Of all breast cancers diagnosed

52% – 1996-2002 African American – Localized – Stage Distribution – Female breast (2007-2008)

53% – African American – Localized (2005–2006)

53% – 1995-2000 (2001) – African American: Diagnosed Female breast (2005-2006): Localized – Of all breast cancers diagnosed
——————————————————————
REGIONAL 5-YEAR RELATIVE SURVIVAL RATES (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)
——————————————————————
82% – 1995-2000 – White
68% – 1995-2000 – African American
——————————————————————
REGIONALLY
——————————————————————
84% – cancer spread regionally, current 5-year survival (2009-2010)

84% – regional disease – 5-year relative survival: Considering all races (2007-2008)

81% – regional disease – 5-year relative survival lower among women with more advanced stage of disease at diagnosis: Considering all races 2005-2006

85% – 1996-2002 White – Regional (2007-2008) *

80% – cancer spread regionally

78% – 2002 – 5-year relative survival rate: breast cancer spread regionally

72% – 1996-2002 African American – Regional (2007-2008) *
——————————————————————
36% – 1996-2002 African American – Regional: Stage Distribution – Female breast (2007-2008)

30% – 1996-2002 White – Regional: Stage Distribution – Female breast (2007-2008)

35% – African American – Regional (2005–2006)

35% – 1995-2000 (2001) – African American: Diagnosed
Female breast (2005-2006): Regional – Of all breast cancers diagnosed

28% – White – Regional (2005–2006)
——————————————————————
REGIONAL TUMORS
——————————————————————
94% – Larger tumor size at diagnosis also associated with decreased survival among women of all races with regional disease, 5-year relative survival for tumors less than or equal (2007-2008)

92% – tumors less than or equal to 2.0 cm – Larger tumor size at diagnosis associated with decreased survival among women of all races with regional disease, 5-year relative survival

77% – tumors 2.1-5.0 cm – Larger tumor size at diagnosis associated with decreased survival among women of all races with regional disease, 5-year relative survival

65% – tumors greater than 5.0 cm – Larger tumor size at diagnosis associated with decreased survival among women of all races with regional disease, 5-year relative survival
——————————————————————
DISTANT
——————————————————————
27% – women with distant spread (metastases) 5-year survival (2009-2010)

27% – 1995-2000 – White – Distant 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)

27% – distant-stage disease: 5-year relative survival, Considering all races (2007-2008)

26% – distant metastasis

26% – distant-stage disease – 2005-2006 5-year relative survival lower among women with more advanced stage of disease at diagnosis: Considering all races

28% – 1996-2002 White – Distant (2007-2008) *

21% – 2002 – 5-year relative survival rate: breast cancer distant metastasis

16% – 1996-2002 African American – Distant (2007-2008) *

15% – 1995-2000 – African American – Distant 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)

28% – 1995-2000 (2001) – White: Distant – Diagnosed Female breast (2005-2006): Of all breast cancers diagnosed
——————————————————————
9% – 1996-2002 African American – Distant – Stage Distribution African Americans – Female breast (2007-2008)

9% – African American – Distant (2005–2006)

9% – 1995-2000 (2001) – African American: Diagnosed
Female breast (2005-2006): Localized – Of all breast cancers diagnosed

6% – 1996-2002 White – Distant – Stage Distribution Whites – Female breast (2007-2008)

5% – White – Distant (2005–2006)
——————————————————————
UNSTAGED
——————————————————————
56% – 1996-2002 – Unstaged – White (2007-2008) *

56% – 1995-2000 – White – Unstaged 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)

50% – 1995-2000 – Unstaged – African American – 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)

45% – 1996-2002 – Unstaged – African American (2007-2008) *
——————————————————————
3% – 1996-2002 African American – Unstaged – Stage Distribution Whites – Female breast (2007-2008)

3% – African American – Unstaged (2005–2006)

3% – 1995-2000 (2001) – African American: Unstaged – Of all breast cancers diagnosed – Diagnosed
Female breast (2005-2006)

2% – 1996-2002 White – Unstaged – Stage Distribution Whites – Female breast (2007-2008)

2% – White – Unstaged (2005–2006)

2% – 1995-2000 (2001) – White: Diagnosed Female breast (2005-2006): Unstaged – Of all breast cancers diagnosed
——————————————————————
ALL – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
90% – 1999-2006 (2011) – 1975-2006
87% – 1992-1999 (2004)
87% – 1992-1999 (2004) – 1974-1999
86% – 1974-1998 (2003)
86% – 1992-1998 (2003) – 1974-1998
86% – 1992-1997 (2002) – 1974-1997
79% – 1984-1986 (2011) – 1975-2006
78% – 1983-1985 (2004)
78% – 1983-1985 (2004) – 1974-1999
78% – 1983-1985 (2002) – 1974-1997
75% – 1975-1977 (2011) – 1975-2006
78% – 1974-1998 (2003)
75% – 1974-1976 (2004)
75% – 1974-1976 (2004) – 1974-1999
75% – 1974-1976 (2002) – 1974-1997
——————————————————————
WHITE WOMEN – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
91% – 1999-2006 (2011) – 1975-2006
90% – 1996-2002 (2007)
88% – 1992-1999 (2004)
88% – 1992-1999 (2004) – 1974-1999
88% – 1992-1998 (2003) – 1974-1998
88% – 1974-1998 (2003)
87% – 1992-1997 (2002) – 1974-1997
81% – 1984-1986 (2011) – 1975-2006
79% – 1983-1985 (2004)
79% – 1983-1985 (2004) – 1974-1999
79% – 1983-1985 (2002) – 1974-1997
76% – 1975-1977 (2011) – 1975-2006
75% – 1974-1976 (2004)
75% – 1974-1976 (2004) – 1974-1999
75% – 1974-1976 (2002) – 1974-1997
——————————————————————
AFRICAN AMERICAN WOMEN – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
78% – 1999-2006 (2011) – 1975-2006
77% – 1996-2002 (2007)
74% – 1992-1999 (2004)
74% – 1992-1999 (2004) – 1974-1999
73% – 1992-1998 (2003) – 1974-1998
73% – 1974-1998 (2003)
72% – 1992-1997 (2002) – 1974-1997
65% – 1984-1986 (2011) – 1975-2006
64% – 1983-1985 (2004)
64% – 1983-1985 (2004) – 1974-1999
63% – 1983-1985 (2002) – 1974-1997
63% – 1974-1998 (2003)
63% – 1974-1976 (2004)
63% – 1974-1976 (2004) – 1974-1999
63% – 1974-1976 (2002) – 1974-1997
62% – 1975-1977 (2011) – 1975-2006
——————————————————————
COMBINED – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
91% – 1999-2006 – White Women – 1975-2006 (2011)
90% – 1999-2006 – All – 1975-2006 (2011)
90% – 1996-2002 – White Women (2007)
87% – 1992-1997 – White Women – 1974-1997 (2002)
86% – 1992-1997 – All – 1974-1997 (2002)
81% – 1984-1986 – White Women – 1975-2006 (2011)
79% – 1984-1986 – All – 1975-2006 (2011)
79% – 1983-1985 – White Women – 1974-1997 (2002)
78% – 1999-2006 – African American Women – 1975-2006 (2011)
78% – 1983-1985 – All – 1974-1997 (2002)
77% – 1996-2002 – African American Women (2007)
76% – 1975-1977 – White Women – 1975-2006 (2011)
75% – 1975-1977 – All – 1975-2006 (2011)
75% – 1974-1976 – All – 1974-1997 (2002)
75% – 1974-1976 – White Women – 1974-1997 (2002)
72% – 1992-1997 – African American Women – 1974-1997 (2002)
65% – 1984-1986 – African American Women – 1975-2006 (2011)
63% – 1983-1985 – African American Women – 1974-1997 (2002)
63% – 1974-1976 – African American Women – 1974-1997 (2002)
62% – 1975-1977 – African American Women – 1975-2006 (2011)
——————————————————————
COMBINED by YEAR – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
91% – 1999-2006 – White Women – 1975-2006 (2011)
90% – 1999-2006 – All – 1975-2006 (2011)
78% – 1999-2006 – African American Women – 1975-2006 (2011)
——————————————————————
90% – 1996-2002 – White Women (2007)
77% – 1996-2002 – African American Women (2007)
——————————————————————
87% – 1992-1997 – White Women (2002)
86% – 1992-1997 – All (2002)
72% – 1992-1997 – African American Women (2002)
——————————————————————
81% – 1984-1986 – White Women – 1975-2006 (2011)
79% – 1984-1986 – All – 1975-2006 (2011)
65% – 1984-1986 – African American Women – 1975-2006 (2011)
——————————————————————
79% – 1983-1985 – White Women (2002)
78% – 1983-1985 – All (2002)
63% – 1983-1985 – African American Women (2002)
——————————————————————
76% – 1975-1977 – White Women – 1975-2006 (2011)
75% – 1975-1977 – All – 1975-2006 (2011)
62% – 1975-1977 – African American Women – 1975-2006 (2011)
——————————————————————
75% – 1974-1976 – All (2002)
75% – 1974-1976 – White Women (2002)
63% – 1974-1976 – African American Women (2002)
——————————————————————
Stages (%) – 5-Year Relative Survival Rates by Stage at Diagnosis
——————————————————————
97.0% – 1992-1999 – Local (2004)
97% – 1992-1998 – Local (2003)
96% – 1992-1997 – Local (2002)
——————————————————————
88% – 2006 – All Stages (2006)
86.6% – 1992-1999 – All Stages (2004)
86% – 1992-1998 – All Stages (2003)
86% – 1992-1997 – All Stages (2002)
——————————————————————
81% – Regional (2006)
78.7% – 1992-1999 – Regional (2004)
78% – 1992-1998 – Regional (2003)
78% – 1992-1997 – Regional (2002)
——————————————————————
26% – 2006 – distant metastases (2006)
23.3% – 1992-1999 – Distant (2004)
23% – 1992-1998 – Distant (2003)
21% – 1992-1997 – Distant metastases (2002)
——————————————————————
*
——————————————————————
1996-2002 – 5-Year Relative Survival Rates (5-year relative survival rate among cancer patients diagnosed 1996-2002 followed through 2003) *

Female breast – (Source: Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1973-2003, Division of Cancer Control and Population Sciences, National Cancer Institute, 2006) (2007-2008)

Local:

invasive cancer confined entirely to organ

Regional:

malignant cancer

1) extended beyond limits of organ of origin directly into surrounding organs or tissues

2) involves regional lymph nodes by way of lymphatic system

3) has both regional extension and involvement of regional lymph nodes

Distant:

cancer spread to parts of body remote from primary tumor either by direct extension or by discontinuous metastasis to distant organs, tissues, or via lymphatic system to distant lymph nodes

Source:

Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1975-2003, Division of Cancer Control and Population Sciences, National Cancer Institute, 2006 (2007-2008)
——————————————————————
5-YEAR SURVIVAL – INVASIVE BREAST CANCER
——————————————————————
90% – 2002-2008 – women diagnosed with invasive breast cancer still living 5 years after getting disease (SEER, 2012)
——————————————————————
10-YEAR SURVIVAL RATES
——————————————————————
Caution should be used when interpreting 10-year survival rates since they represent detection and treatment circumstances 5-17 years ago and may underestimate expected survival based on current conditions (2009-2010)

Caution should be used when interpreting long-term survival rates since they reflect experience of women treated using past therapies and do not reflect recent trends in early detection or advances in treatment (2007-2008)
——————————————————————
87% – White – 10 year survivors after diagnosis relative 5 year survival rate (2005-2006)
——————————————————————
85% – African American – 10 year survivors after diagnosis relative 5 year survival rate (2005-2006)
——————————————————————
81% – 10 year – relative survival rates for women diagnosed with breast cancer (2007-2008)
——————————————————————
80% – 10 year – survival rate for all stages combined (2009-2010)
——————————————————————
80% – 10 years after diagnosis – relative survival rates for women diagnosed with breast cancer (2005-2006)
——————————————————————
77% – 10 year – Breast Cancer Survival Rates after Diagnosis (2005-2006)
——————————————————————
15-YEAR SURVIVAL RATE
——————————————————————
73% – 15 year – relative survival rates for women diagnosed with breast cancer (2007-2008)
——————————————————————
71% – 15 years after diagnosis – relative survival rates for women diagnosed with breast cancer (2005-2006)
——————————————————————
63% – 15 years – Breast Cancer Survival Rates after Diagnosis (2005-2006)
——————————————————————
20-YEAR SURVIVAL RATE
——————————————————————
63% – 20 years after diagnosis – relative survival rates for women diagnosed with breast cancer (2005-2006)
——————————————————————
52% – 20 years – Breast Cancer Survival Rates after Diagnosis (2005-2006)
======================================
Breast Cancer
American Cancer Society
Cancer Facts & Figures (2002-2014)

======================================
REFERENCES:
======================================
[A] – .7/30/2013, Tuesday – Karmanos Cancer Center’s Dr. David Gorski appointed program co-director of Michigan Breast Oncology Quality Initiative:
——————————————————————
http://www.karmanos.org/News/Default.aspx?sid=1&nid=359
======================================
[B] – .7/30/2013 – Dr. Gorski named co-director of Michigan Breast Oncology Quality Initiative:
——————————————————————
http://prognosis.med.wayne.edu/article/dr-gorski-named-codirector-of-michigan-breast-oncology-quality-initiative
======================================
[C] – 07/30/2013 – Dr. Gorski named co-director of Michigan Breast Oncology Quality Initiative : ——————————————————————
http://www.wsupgdocs.org/news-and-media/WayneStateContentPage.aspx?nd=1293&news=515
======================================
[D] – 2/1/2011 – Barbara Ann Karmanos Cancer Center Names Dr. David Gorski Leader of Breast Multidisciplinary Team:
/PRNewswire-USNewswire/ — The Barbara Ann Karmanos Cancer Center has named David Gorski, M.D., Ph.D., leader of the Breast Multidisciplinary Team (MDT), effective Tuesday, Feb. 1
——————————————————————
http://m.prnewswire.com/news-releases/barbara-ann-karmanos-cancer-center-names-dr-david-gorski-leader-of-breast-multidisciplinary-team-115018114.html
======================================
[E] – 11/2/2011, Wednesday – Make the Right Move:
——————————————————————
http://www.karmanos.org/News/breast-cancer-specialists
======================================
[F]
——————————————————————
http://cancerbiologyprogram.med.wayne.edu/faculty/gorski.php
======================================
[G] – Research Interest:
——————————————————————
http://www.wsusurgery.com/research-team-dr-gorski/
======================================
[H]
——————————————————————
http://wsusurgery.com/facultyc3/david-gorski/
——————————————————————
http://www.wsusurgery.com/facultyc3/david-gorski/
======================================
[I]
——————————————————————
http://wsusurgery.com/research-team-dr-gorski/
——————————————————————
http://www.wsusurgery.com/research-team-dr-gorski/
======================================
[J]
——————————————————————
http://karmanos.org/Physicians/Details.aspx?sid=1&physician=70
——————————————————————
http://www.karmanos.org/Physicians/Details.aspx?sid=1&physician=70
======================================
[K]
——————————————————————
http://sciencebasedmedicine.org/editorial-staff/
——————————————————————
http://www.sciencebasedmedicine.org/editorial-staff/
======================================
[L]
——————————————————————
http://www.scienceinmedicine.org/fellows/GorskiD.html
——————————————————————
http://scienceinmedicine.org/fellows/GorskiD.html
======================================
[M]
——————————————————————
http://sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/
——————————————————————
http://www.sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/
======================================
[N]
——————————————————————
http://scienceblogs.com/insolence
======================================
[O]
——————————————————————
http://ncas.org/2013/02/mar-9-david-h-gorski-quackademic.html?m=1
——————————————————————
http://www.ncas.org/2013/02/mar-9-david-h-gorski-quackademic.html?m=1
======================================
[P]
——————————————————————
http://whybiotech.com/?p=3808
——————————————————————
http://www.whybiotech.com/?p=3808
======================================
[Q]
——————————————————————
http://en.wikipedia.org/wiki/David_Gorski
======================================
[R] – Breast Cancer Research – Dr. Gorski:
——————————————————————
http://www.wsusurgery.com/breast-cancer-research-dr-gorski/
======================================
[S] – Selected Publications:
——————————————————————
http://www.wsusurgery.com/selected-publications-dr-gorski/
======================================
[T] – Lab Photos:
——————————————————————
http://www.wsusurgery.com/lab-photos-dr-gorski/
======================================
[U]
——————————————————————
https://www.doximity.com/pub/david-gorski-md
======================================
[V] – Detroit, Michigan population
——————————————————————
http://www.worldpopulationstatistics.com/detroit-population-2013/
======================================
[W]
——————————————————————
http://quickfacts.census.gov/qfd/states/26/2622000.html
======================================
[X]
——————————————————————
http://www.city-data.com/city/Detroit-Michigan.html
======================================
[Y] – 11/13/2013 – The War on Cancer (I don’t think it means, what you think it says it means) #Winning?:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/13/httpcancer-orgacsgroupscontentepidemiologysurveilancedocumentsdocumentacspc-036845-pdf/
======================================
[Z] – 3/9/2013 – Quackademic Medicine: How pseudoscience is infiltrating medical academia.”
——————————————————————
http://m.youtube.com/watch?v=mewOSMNgfGQ&desktop_uri=%2Fwatch%3Fv%3DmewOSMNgfGQ
======================================
[]
——————————————————————
http://www.nixonlibrary.gov/forresearchers/find/tapes/excerpts/watergate.php
——————————————————————
http://whitehousetapes.net/transcript/nixon/cancer-presidency
——————————————————————
http://m.washingtonpost.com/politics/cancer-on-the-presidency/2012/06/08/gJQAp24LOV_video.html
——————————————————————
http://www.history.com/speeches/nixon-and-dean-discuss-watergate
======================================
2013-2014 Breast Cancer Facts & Figures
——————————————————————

Click to access acspc-040951.pdf

——————————————————————

Click to access acspc-040951.pdf

——————————————————————
2013-2014 Cancer Facts & Figures for African Americans
——————————————————————

Click to access acspc-036921.pdf

——————————————————————

Click to access acspc-036921.pdf

——————————————————————
2012-2014 Cancer Facts & Figures for Hispanics / Latinos
——————————————————————

Click to access acspc-034778.pdf

——————————————————————

Click to access acspc-034778.pdf

======================================
2013 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013
——————————————————————
2013-2014 Cancer Facts & Figures
——————————————————————

Click to access acspc-040951.pdf

——————————————————————

Click to access acspc-040951.pdf

——————————————————————

——————————————————————
http://onlinelibrary.wiley.com/doi/10.3322/caac.21203/full
——————————————————————
2013
——————————————————————

Click to access breast-cancer-facts-2012.pdf

——————————————————————

Click to access breast-cancer-facts-2012.pdf

——————————————————————
2012-2013 Survivorship
——————————————————————

Click to access acspc-033876.pdf

——————————————————————

Click to access acspc-033876.pdf

——————————————————————
2013 – Cancer Facts & Figures
——————————————————————

Click to access acspc-036845.pdf

——————————————————————

Click to access acspc-036845.pdf

——————————————————————
2013 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index
======================================
2011-2012 Breast Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts-and-figures-2011-2012
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts-and-figures-2011-2012
——————————————————————
Breast Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/breast-cancer-facts-figures
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/breast-cancer-facts-figures
——————————————————————
2012 – Cancer Facts & Figures
——————————————————————

Click to access acspc-031941.pdf

——————————————————————

Click to access acspc-031941.pdf

——————————————————————
2012 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2012/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2012/index
——————————————————————
2012 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012
——————————————————————
2011-2012 Cancer Facts & Figures for African Americans
——————————————————————

Click to access acspc-027765.pdf

——————————————————————

Click to access acspc-027765.pdf

======================================
2011 – Cancer Facts & Figures
——————————————————————

Click to access acspc-029771.pdf

——————————————————————

Click to access acspc-029771.pdf

——————————————————————
2011 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2011
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2011
——————————————————————
2009-2011 Cancer Facts & Figures for Hispanics / Latinos
——————————————————————

Click to access ffhispanicslatinos20092011.pdf

——————————————————————

Click to access ffhispanicslatinos20092011.pdf

======================================
2010
——————————————————————
http://cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts-figures-2009-2010
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts-figures-2009-2010
——————————————————————
2009-2010 Breast Cancer Facts & Figures
——————————————————————

Click to access f861009final90809pdf.pdf

——————————————————————

Click to access f861009final90809pdf.pdf

——————————————————————
2010 – Cancer Facts & Figures
——————————————————————

Click to access acspc-024113.pdf

——————————————————————

Click to access acspc-024113.pdf

——————————————————————
2010 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2010/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2010/index
——————————————————————
2009-2010 Cancer Facts & Figures for African Americans
——————————————————————

Click to access cffaa20092010pdf.pdf

——————————————————————

Click to access cffaa20092010pdf.pdf

======================================
2009
——————————————————————
http://www.komenstlouis.org/site/DocServer/DiversityAsianPacific.pdf?docID=222
——————————————————————
2009-2010 Cancer Facts & Figures for African Americans
——————————————————————

Click to access cffaa20092010pdf.pdf

——————————————————————

Click to access cffaa20092010pdf.pdf

——————————————————————
2009 – Cancer Facts & Figures
——————————————————————

Click to access 500809webpdf.pdf

——————————————————————

Click to access 500809webpdf.pdf

——————————————————————
2009 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2009/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2009/index
——————————————————————
2009 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2009
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2009
======================================
Breast Cancer Facts & Figures
——————————————————————
http://www.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/
——————————————————————
2007-2008 Breast Cancer Facts & Figures
——————————————————————

Click to access bcfffinalpdf.pdf

——————————————————————

Click to access bcfffinalpdf.pdf

——————————————————————
Cancer Facts and Statistics
——————————————————————
http://cancer.org/research/cancerfactsstatistics/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/index
——————————————————————
2008 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
2008 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2008/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2008/index
——————————————————————
2008 – Cancer Facts & Figures
——————————————————————

Click to access 2008cafffinalsecuredpdf.pdf

——————————————————————

Click to access 2008cafffinalsecuredpdf.pdf

——————————————————————
2008 – Cancer Facts & Figures
——————————————————————

Click to access worldcancer.pdf

——————————————————————

Click to access worldcancer.pdf

——————————————————————
Global
——————————————————————

Click to access acspc-027766.pdf

——————————————————————

Click to access acspc-027766.pdf

——————————————————————
2008 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2008/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2008/index
——————————————————————
Cancer Facts and Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
======================================
2007-2008 Breast Cancer Facts & Figures
——————————————————————

Click to access bcfffinalpdf.pdf

——————————————————————

Click to access bcfffinalpdf.pdf

——————————————————————

——————————————————————
http://komen.org/BreastCancer/BreastFactsReferences.html
——————————————————————

——————————————————————
http://ww5.komen.org/BreastCancer/BreastFactsReferences.html
——————————————————————
2007 – Cancer Facts & Figures
——————————————————————

Click to access caff2007pwsecuredpdf.pdf

——————————————————————

Click to access caff2007pwsecuredpdf.pdf

——————————————————————
2007 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2007/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2007/index
——————————————————————
2007 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2007
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2007
——————————————————————
2007-2008 Cancer Facts & Figures for African Americans
——————————————————————

Click to access caff2007aaacspdf2007pdf.pdf

——————————————————————

Click to access caff2007aaacspdf2007pdf.pdf

——————————————————————
2006-2008 Cancer Facts & Figures for Hispanics / Latinos
——————————————————————

Click to access caff2006hisppwsecuredpdf.pdf

——————————————————————

Click to access caff2006hisppwsecuredpdf.pdf

======================================
2006 – Cancer Facts & Figures
——————————————————————

Click to access caff2006pwsecuredpdf.pdf

——————————————————————

Click to access caff2006pwsecuredpdf.pdf

——————————————————————
2006 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2006
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2006
——————————————————————
2005-2006 Breast Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts–figures-2005-2006
——————————————————————
2005-2006 Breast Cancer Facts & Figures
——————————————————————

Click to access caff2005brfacspdf2005pdf.pdf

——————————————————————

Click to access caff2005brfacspdf2005pdf.pdf

——————————————————————
2005-2006 Breast Cancer Facts & Figures
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts–figures-2005-2006
——————————————————————
2005-2006 Cancer Facts & Figures for African Americans
——————————————————————

Click to access caff2005aacorrpwsecuredpdf.pdf

——————————————————————

Click to access caff2005aacorrpwsecuredpdf.pdf

======================================
2005 – Cancer Facts & Figures
——————————————————————

Click to access caff2005f4pwsecuredpdf.pdf

——————————————————————

Click to access caff2005f4pwsecuredpdf.pdf

——————————————————————

——————————————————————
http://worldwidebreastcancer.com/learn/breast-cancer-statistics-worldwide/
——————————————————————

——————————————————————
http://www.worldwidebreastcancer.com/learn/breast-cancer-statistics-worldwide/
——————————————————————
Cancer Facts and Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
2005 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2005
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2005
======================================
2003-2004 Breast Cancer Facts & Figures
——————————————————————

Click to access caff2003brfpwsecuredpdf.pdf

——————————————————————

Click to access caff2003brfpwsecuredpdf.pdf

——————————————————————
2004 – Cancer Facts & Figures
——————————————————————

Click to access CancerRates2004.pdf

======================================
2003
——————————————————————
http://cancer.org/cancer/breastcancer/detailedguide/breast-cancer-references
——————————————————————
http://m.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-references
——————————————————————
2003 – Cancer Facts & Figures
——————————————————————

Click to access 2003_ACS_Cancer_Facts.pdf

======================================
2002 – American Cancer Society Cancer Facts & Figures
——————————————————————

Click to access acspc-027766.pdf

——————————————————————

Click to access acspc-027766.pdf

——————————————————————
2002 – Cancer Facts & Figures
——————————————————————

Click to access CancerFacts&Figures2002.pdf

======================================

Advertisement
Posted in American Cancer Society, Antineoplastons (ANP), bias, biased, BIG Pharma, critique, critiques, critiqued, critiquing, Gorski ScienceBlogs.com/Insolence ScienceBasedMedicine, Richard A. Jaffe, Stanislaw Rajmund Burzynski, The Skeptics | Tagged "10-years", "5-year", "5th Circuit Court of Appeals", "academic surgical oncologist", "Advanced Clinical Research Award in Breast Cancer", "African American", "African Americans", "Alaska Native", "Alaskan Native", "Alexander J. Walt Comprehensive Breast Center", "alma-mater", "American Board of Surgery", "American Cancer Society Cancer Facts & Figures", "American Cancer Society Cancer Facts and Figures", "American Cancer Society", "American College of Surgeons Committee on Cancer (ACS CoC)", "American College of Surgeons Committee on Cancer", "American Indian", "American Society of Clinical Oncology", "Ann Karmanos Cancer Center", "Ann Karmanos Cancer Institute", "antineoplastons (ANPs)", "Assistant Professor of Surgery", "Associate Professor of Surgery and Oncology at the Wayne State University School of Medicine, "associate professor of surgery and Oncology", "Associate Professor of Surgery", "Attending Surgeon", "B.S.", "Barbara Ann Karmanos Cancer Center / Institute", "Barbara Ann Karmanos Cancer Center", "Barbara Ann Karmanos Cancer Institute", "Barbara Ann Karmanos Cancer", "Barbara Ann Karmanos", "Board of Directors", "Breast Cancer Biology Program", "Breast Cancer Facts and Figures", "Breast Cancer Multidisciplinary Team (MDT)", "breast cancer", "Breast Surgery Section", "breast surgery", "Burzynski’s lawyer", "Cancer Committee", "Cancer Facts and Figures", "Cancer Liaison Physician for the American College of Surgeons Committee on Cancer", "Cancer Liaison Physician", "cancer therapies", "cancer.org/acs/", "cancer.org/acs/" "m.cancer.org/acs/", "cancer.org/acs/groups/", "cancer.org/acs/groups/content/", "cancer.org/acs/groups/content/@epidemiologysurveilance/", "cancer.org/acs/groups/content/@epidemiologysurveilance/documents/", "cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/", "cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf", "cancer.org/acs/groups/content/@nho/documents/document/caff2003brfpwsecuredpdf.pdf", "cancer.org/cancer/breastcancer/detailedguide/breast-cancer-references", "cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2005", "Cancer: It’s what’s Best for Business (WW3 – World War Hypocrisy) | Didymus Judas Thomas' Hipocritical Oath Blog https://stanislawrajmundburzynski.wordpress.com/2013/12/14/cancer-its-whats-good-, "Cancer: It’s what’s Best for Business (WW3 – World War Hypocrisy) | Didymus Judas Thomas' Hipocritical Oath Blog", "Case Western Reserve University", "Case Western", "cellular physiology", "Cleveland Clinic", "clinical champion", "clinical research", "Co-Chair", "co-director", "Co-Leader", "Co-Medical Director", "Company’s operations”, "Comprehensive Breast Center", "Conquer Cancer Foundation", "D.H. Gorski", "DH Gorski", "Dr. Burzynski's", "Dr. David Gorski", "Dr. David H. “Orac” Gorski", "Dr. Gorski", "ethnic group", "evidence-based", "five-year", "General Surgery", "Graduate Program in Cancer Biology", "H.H.H.", "head of its childhood immunization committee", "HHH", "high-quality", "hormonal therapy", "http://cancer.org/acs/groups/content/@epidemiologysurveilance/", "http://cancer.org/acs/groups/content/@epidemiologysurveilance/documents/", "http://cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/", "http://cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf", "http://cancer.org/acs/groups/content/@nho/documents/document/caff2003brfpwsecuredpdf.pdf", "http://cancer.org/cancer/", "http://cancer.org/cancer/breastcancer/" "http://m.cancer.org/cancer/breastcancer/" "http://cancer.org/cancer/breastcancer/detailedguide/", "http://cancer.org/cancer/breastcancer/detailedguide/", "http://cancer.org/cancer/breastcancer/detailedguide/breast-cancer-references", "http://cancer.org/research/", "http://cancer.org/research/cancerfactsstatistics/", "http://cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/" "http://m.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/", "http://m.cancer.org/", "http://m.cancer.org/acs/", "http://m.cancer.org/acs/groups/", "http://m.cancer.org/acs/groups/content/", "http://m.cancer.org/acs/groups/content/@epidemiologysurveilance/", "http://m.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/", "http://m.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/", "http://m.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf", "http://m.cancer.org/acs/groups/content/@nho/documents/document/caff2003brfpwsecuredpdf.pdf", "http://m.cancer.org/cancer/", "http://m.cancer.org/cancer/breastcancer/", "http://m.cancer.org/cancer/breastcancer/detailedguide/", "http://m.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-references", "http://m.cancer.org/research/", "http://m.cancer.org/research/cancerfactsstatistics/", "https://stanislawrajmundburzynski.wordpress.com/2013/12/14/cancer-its-whats-good-for-business/", "Hunter Hearst Helmsley", "in situ breast cancer", "Institute for Science in Medicine", "It’s what’s Best for Business", "Joint Graduate Program in Cell & Developmental Biology at Rutgers University in Piscataway, "Karmanos Cancer Center", "life time", "Long-term", "Lutheran General Hospital, "m.cancer.org/", "m.cancer.org/acs/", "m.cancer.org/acs/groups/", "m.cancer.org/acs/groups/content/", "m.cancer.org/acs/groups/content/@epidemiologysurveilance/", "m.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/", "m.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/", "m.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf", "Managing Editor", "medical degree (M.D.)", "Medical Director of the Alexander J. Walt Comprehensive Breast Center", "medical director", "medical practice", "member of the faculty of the Graduate Program in Cancer Biology", "Michigan Breast Oncology Quality Initiative", "Michigan State Medical License", "National Geographic", "natural born killer", "new program co-director", "NON-citations", "NON-links", "NON-references", "Ohio State Medical License", "once-weekly", "Pacific Islander", "Physician Group surgeon", "project director", "Q.M.", "Quackademic Duck", "Red Badge of Courage", "Richard Milhous Nixon", "Robert Wood Johnson Medical School, "Saul Green", "School of Medicine", "Science-Based Medicine weblog", "Science-Based", "ScienceBasedMedicine . org", "site project director", "six times the national average", "St. Peter’s University Hospital, "state-wide", "Stephanie McMahon", "success stories”, "Surgical Oncology and General Surgery", "Surgical Oncology", "team leader", "The Cancer Institute of New Jersey", "The Cerebral Assassin", "Trauma Services", "Treasurer for the Institute for Science in Medicine", "trickle-down", "Tricky-Dicky", "Triple H", "U.S.", "Ultra-diluted", "UMDNJ-Robert Wood Johnson Medical School in New Brunswick, "United States of America", "University Hospitals Case Medical Center Internship", "University Hospitals Case Medical Center Residency", "University of Chicago Fellowship", "University of Michigan Medical School", "University of Michigan", "University of Michigan" Gorski http://en.wikipedia.org/wiki/David_Gorski, "vis-a-vis", "W.W.E.", "War on Cancer", "Wayne State University School of Medicine", "Wayne State University School", "Wayne State University", "web-site", "whyquit.com/", "woman's", "Women’s", "World War Hypocrisy", "World Wrestling Entertainment", "www.pink-ribbon-pins.com/", "www.pink-ribbon-pins.com/CancerRates2004.pdf", "www.uhmsi.com/", "www.uhmsi.com/docs/", "www.uhmsi.com/docs/CancerFacts&Figures2002.pdf", "www.whyquit.com/", "www.whyquit.com/studies/", "www.whyquit.com/studies/2003_ACS_Cancer_Facts.pdf", #ACS, #FAIL, #sciencebasedmedicine, #TripleH, #UniversityofMichigan, #WWE, 2nd, @gorskon, @oracknows, @ScienceBasedMed, ability, able, about, academic, Academically, accounted, accounting, acknowledged, active, add, added, address, advanced, advances, Adverse, African, again, age, ages, aggressive, Alaska, Alaskan, ALL, Almost, also, ALTERNATIVE, although, alum, American, AmericanCancerSociety, among, anecdotal, animosity, Ann Arbor, annual, annually, ANP, antineoplaston, antineoplastons, any, anything, appeared, appearing, applies, approved, articles, ASCO "Breast Cancer Research Foundation", Asian, assess, associate, associated, attempted, attended, attending, awaiting, aware, “Alternative Rock“, “Big Pharma”, “cure” cancer, “former employer, “Gorski Patent Group”, “Our only goal is to promote high standards of science in medicine”, “Quackademic” line, “too many people copulating”, ” "UMDNJ (University of Medicine and Dentistry of New Jersey)", bad, based, bear, beat, been, being, believe, bemoans, benefited, best, between, beyond, BIG, bigot, billions, Birth, Births, bitten, Black, blatant, blogs, Both, braying, breast, Breast Cancer Facts & Figures", breasts, breathes, Burzynski Clinic, Cancer, Cancer Facts & Figures", cancer.org., cancerous, cancers, carcinoma, care, cases, cause, Caution, Center, centers, change, changed, characteristics, Chemistry, chemotherapeutic, CHEMOTHERAPY, Chief of the Section of Breast Surgery", choices, chose, circumstances, citation(s), city, Claim, claimed, classify, Cleveland, Clinical Trials, closet, colorectum, combine, combined, comes, comment, common, communist, compared, condition, conditions, confused, Considering, constant, continue, continued, Contributor, creature, critique, critiqued, critiques, Critiquing, CURE, cured, current, Currently, D.", D.H.", David Gorski, David H. Gorski, day, DCIS, dead, death, deaths, decade, decades, decided, decideMaybe, decline, declined, decreases, decreasing, dedication, Despite, detection, Detroit, develop, developed, developing, DH", diagnose, diagnosed, diagnoses, diagnosing, diagnosis, die, dies, difference, different, difficult, disease, disparity, display, displays, Distant, Distinction, divergence, documented, does, dollars, doubt, Dr. David H. Gorski, drugs, ductal, due, dying, each. stage, early, effective, Effects, efficacy, egg, entities, equal, essential, essentially, estimate, estimated, estimates, ethnic, Ethnicity, even, every, everyone, evidence, exists, expanded, expansion, expect, expectancy, expected, experience, F.A.C.S.", Facebook, FACS", factoid, faculty, Failure, FDA, Federal Courts, felt, Female, Females, financial, fines, formulate, from, fund, gene, general, getting, glutton, god, Golden, goose, GorskGeek, Gorski, gradually, Graduation, greater, greatest, groups, guidelines, gun, Hackademic, hang, happiness, hard, harm, harmful, Has, hates, have, head, high, higher, highest, hilariously, Hippocratic, his, Hispanic, Hispanics, Homeopathy, Honors, hormonal, how, http//www.sciencebasedmedicine.org, http://cancer.org/, http://cancer.org/acs/, http://cancer.org/acs/groups/, http://cancer.org/acs/groups/content/, http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2005, http://cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index, http://cancerbiologyprogram.med.wayne.edu/, http://cancerbiologyprogram.med.wayne.edu/faculty/, http://cancerbiologyprogram.med.wayne.edu/faculty/gorski.php, http://karmanos.org/Physicians/Details.aspx?sid=1&physician=70, http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2005, http://m.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index, http://med.wayne.edu/, http://med.wayne.edu/surgery/, http://med.wayne.edu/surgery/faculty/DGorski.html, http://ncas.org/2013/02/mar-9-david-h-gorski-quackademic.html?m=1, http://pink-ribbon-pins.com/, http://prognosis.med.wayne.edu/article/dr-gorski-named-codirector-of-michigan-breast-oncology-quality-initiative, http://sciencebasedmedicine.org, http://sciencebasedmedicine.org/editorial-staff/, http://sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/, http://scienceblogs.com/, http://scienceblogs.com/Insolence, http://uhmsi.com/, http://uhmsi.com/docs/, http://uhmsi.com/docs/CancerFacts&Figures2002.pdf, http://whybiotech.com/?p=3808, http://wsusurgery.com/facultyc3/david-gorski/, http://wsusurgery.com/research-team-dr-gorski/, http://www.cancerbiologyprogram.med.wayne.edu/, http://www.cancerbiologyprogram.med.wayne.edu/faculty/, http://www.cancerbiologyprogram.med.wayne.edu/faculty/gorski.php, http://www.karmanos.org/Physicians/Details.aspx?sid=1&physician=70, http://www.med.wayne.edu/, http://www.med.wayne.edu/surgery/faculty/, http://www.med.wayne.edu/surgery/faculty/DGorski.html, http://www.ncas.org/2013/02/mar-9-david-h-gorski-quackademic.html?m=1, http://www.pink-ribbon-pins.com/, http://www.pink-ribbon-pins.com/CancerRates2004.pdf, http://www.sciencebasedmedicine.org/editorial-staff/, http://www.sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/, http://www.scienceblogs.com/, http://www.scienceblogs.com/Insolence, http://www.uhmsi.com/, http://www.uhmsi.com/docs/, http://www.uhmsi.com/docs/CancerFacts&Figures2002.pdf, http://www.whybiotech.com/?p=3808, http://www.whyquit.com/, http://www.whyquit.com/studies/, http://www.whyquit.com/studies/2003_ACS_Cancer_Facts.pdf, http://www.wsusurgery.com/facultyc3/david-gorski/, http://www.wsusurgery.com/research-team-dr-gorski/, https://mobile.twitter.com/, https://mobile.twitter.com/gorskon, https://mobile.twitter.com/oracknows, https://mobile.twitter.com/rjblaskiewicz, https://mobile.twitter.com/ScienceBasedMed, https://twitter.com/, https://twitter.com/gorskon, https://twitter.com/oracknows, https://twitter.com/ScienceBasedMed, https://www.twitter.com/gorskon, https://www.twitter.com/oracknows, https://www.twitter.com/ScienceBasedMed, hurricane, Hypocrite, hypocuresy, I, Illinois", immunotherapy, improve, improved, incidence, Incidences, include, increase, increased, increases, Indeed, Indian, ineffective, infiltrated, infiltration, initiative, injury, instead, insult, Internet, interpreting, into, invasive, Islander, issues, joining, joke, just, Karmanos, Katrina, knew, known, largely, larger, largest, later, Latinas, LCIS, leading, led, less, leveling, LIES. Orac, life, Lifetime, likely, limited, link(s), literary Hack, little, loaded, Lobular, local, localized, locals, locations, Louisiana, lower, lucky, lymph, M.D.", makes, matter, may, Maybe, MD", medical, medications, medicine, member, members, mentioned, Mentions, metastases, MetroHealth, MiBOQI, Michigan, might, mighty, minorities, mistake, more, mortal, Mortality, most, much, Mudicine, must, my, N.J.", NatGeo, Native, nearest, needs, nest, new, New Brunswick, New Jersey", newly, NJ", nodes, noted, nothing, number, oath, oblivious, occur, occurs, off, Ohio", old, older, oncologic, oncology, opprobrium, opted, options, Orac, Oracolyte, Oracolytes, ordinary, other, others, otherwise, outside, over, overall, own, Pacific, paid, Parachute, Park Ridge, particular, Particularly, partnership, past, patients, percentage, Ph.D, Pharma, PhD, phrase, ploy, population, populous, possibly, postmenopausal, potential, potentially, practice, practices, predominantly, present, Presidency, prior, Probability, Probable, problem, Professor", prompt, pseudoscientific, public, punishment, Quackademic Medicine, Quality, queued, race, races, racial, racist, racked, RADIATION, radio, raising, ranks, rant, rapid, rate, Rates, rather, Ratio, Ratios, really, Reason, receipt, receive, received, recent, References, referring, regards, Regional, regionally, relative, relatively, remained, remarking, represent, requirements, research, residency, Resident, Respectful Insolence, Response, responsive, result, Richard Jaffe, risk, risks, rival, rounding, rule, saying, SBM, scienceblogs, seeming, seems, SEER, serves, set, sevenfold, several, Sex, shame, shortest, should, significantly, since, site, sites, Skeptical, skunk, sleeps, slightly, slowly, somewhat, soon, specialize, specializing, spend, spread, stabilized, Stable, stage, stages, State, states, stink, stories", story, striking, studies, success, such chemotherapy, supply, supported, sure, surely, surgery, Surgical, surprised, survival, survivors, symptoms, take, targeted, than, their, theory, therapy, these, they, through, thus, tied, time, tirelessly, told, toolbox, total, toward, traditional, Treasurer, treatment, Trends, tried, tries, try, tumor, tumors, turn, TV, Twitter, UMDNJ, unapproved, Under”, underestimate, underrepresented, unequal, United States, unproved, Unstaged, unwitting, USA, use, used, using, usual, utilize, view, was, well, well member, were, WHAT, when, where, which, white, white woman, whites, who, whole, wilderness, with, within, wolverine, women, words, work, worked, worse, would, wtraditional cancer treatment options in order to be eligible to participate in the Company’s Antineoplaston clinical trials“, WW3, Year, Years, yet, young, younger | Leave a reply

Critiquing: Stanislaw Burzynski in USA Today: Abuse of clinical trials and patients versus the ineffectiveness of the FDA and Texas Medical Board (Josia Cotto)

Posted on November 20, 2013 by didymusjudasthomas
Reply

David H. Gorski, M.D., Ph.D., FACS “Check My Facts” Hack “Orac”, finally ends his 11/15/2013 diatribe of Dr. Burzynski by USA TODAY’s Liz Szabo, Michael Stravato, Jerry Mosemak, and Robert Hanashiro, with:
——————————————————————
“The concluding section of the story tells us why we need to try:”

“No one told Josia’s parents about any of this”

“Not Burzynski”

“Not the FDA”

“Jose and Niasia Cotto had no idea that their son’s death prompted an investigation by the FDA, until they were contacted by USA TODAY”

“The Cottos had long believed that Burzynski could have cured their son if only they had taken Josia to see him first, before giving him radiation and chemotherapy”

“They had even hoped to launch a non-profit, A Life for Josia Foundation, to help other children with cancer gain access to Burzynski’s treatment“

“Now, they don’t know what to think”
——————————————————————
So what good did Gorski do here, if any ?

1. He offers no opinion as to if he thinks Burzynski should have been responsible for advising Jose and Niasia Cotto that Josia Cotto’s death prompted an investigation by the FDA

2. He offers no opinion as to if he thinks the FDA should have been responsible for advising Jose and Niasia Cotto that Josia Cotto’s death prompted an investigation

3. He offers no opinion as to if he thinks Burzynski could have cured Jose and Niasia Cotto’s son, Josia Cotto’s if only they had been able to take Josia to Burzynski first

4. He offers no opinion as to what he thinks about the FDA requiring Josia Cotto to receive radiation and chemotherapy, and them failing Josia, before he was able to utilize antineoplaston therapy

Gorski might as well NOT even be here if all he’s going to do is repost the same thing USA TODAY published, yet “say” absolutely NOTHING

Personally, I think it’s has to do with what was said during the July TAM 2013 twaddle, when the female panelist made a comment about “people without BALLS”
——————————————————————
Since I have mine, here’s what I think:

1. If there was a moral or legal duty to advise Jose and Niasia Cotto that the passing of Josia prompted an investigation by the FDA, then it was the FDA’s responsibility

2. I think that if the FDA was NOT requiring patients like Josia Cotto to 1st be failed by conventional treatments like surgery, radiation, and / or chemotherapy, there is a chance that Burzynski’s antineoplaston therapy could be more effective because of:
======================================
What USA TODAY, Liz Szabo, Michael Stravato, Jerry Mosemak, and Robert Hanashiro DID NOT TELL YOU ABOUT:
——————————————————————
12/2002 Burzynski interview [3]
——————————————————————
INTRAVENOUS
——————————————————————
1. Treatment require strong commitment from patients as must be infused with Antineoplastons for many weeks or months ?
——————————————————————
2. Perhaps 15% of patients taking intravenous infusions of Antineoplastons
——————————————————————
3. Patients who have most advanced type of cancer will require heavy dosages
——————————————————————
4. When give large dosages intravenously, have to watch fluid balance…and electrolyte balance
——————————————————————
5. Intravenous infusion can deliver equivalent of 3,000 tablets a day
——————————————————————
ORAL – CAPSULES OR TABLETS
——————————————————————
1. Most patients taking oral formulations
——————————————————————
2. Capsules or tablets
——————————————————————
3. Limitation of how much medicine can take by mouth
——————————————————————
4. 50 or 60 tablets a day pretty much all you can take by mouth
——————————————————————
5. When give orally, see practically no side effects at all
——————————————————————
6. Patients may develop skin rash, which may last for day or two
——————————————————————
7. Don’t see any delayed toxicity once treatment stops
——————————————————————
8. Everything practically goes back to normal within day or two
——————————————————————
9. Doesn’t even come close to adverse reactions that experience with chemotherapy
——————————————————————
FDA requirements
——————————————————————
1. Most patients who come to us have received prior heavy radiation therapy, or chemotherapy
——————————————————————
2. Usually die from complications from these treatments
——————————————————————
3. Those who survive longest are patients who previously did not receive radiation therapy or chemotherapy
——————————————————————
4. Longest survivor in this category is now reaching 15 years from time of diagnosis; and she’s in perfect health
——————————————————————
12/10/1997 [4]
——————————————————————
1. In addition to original family of Antineoplaston compounds

(the “Parental Generation”)
——————————————————————
2. Development of 2nd generation of Antineoplastons

In cell culture experiments 2nd generation Antineoplastons developed have been shown to be at least

Thousand times more potent then
Parental Generation
——————————————————————
3. 3rd generation structurally altered Antineoplaston believe will exhibit markedly improved anticancer activity in human cancer cell lines resistant to
Parental Generation

—————————————————————
12/2000 Egypt antineoplaston study [5]
——————————————————————
4 new piperidinedione A10 analogs synthesized and tested on human breast cancer cell line against prototype A10 and anti cancer drug tamoxifen and DNA binding capacity of compounds evaluated against A10
——————————————————————
“3B” and “3D” were several-fold more potent antiproliferative agents than A10 and tamoxifen and had significantly higher capacity to bind DNA than A10
—————————————————————
10/1/2001 Egypt antineoplaston study [5]
——————————————————————
Structural characterization of new antineoplaston (ANP) representatives
——————————————————————
Combination heat with pH modification had virtually no effect on obtained peaks, attesting to stability and purity of compounds
——————————————————————
One had superior affinity to DNA than
prototype ANP-A10

======================================
So, what do we know from this interview with Burzynski from over a decade ago, his 12/10/1997 Securities and Exchange Commission (SEC) filing and the antineoplaston research from Egypt ?
——————————————————————
1. Oral (capsule and tablets): PRACTICALLY NO SIDE EFFECTS at all
——————————————————————
2. Those who survive longest are patients who previously did NOT receive radiation therapy or chemotherapy
——————————————————————
3. 2nd generation of Antineoplastons have been shown to be at least a THOUSAND TIMES MORE POTENT then Parental Generation
——————————————————————
4. 3rd generation structurally altered Antineoplaston believe will exhibit markedly improved anticancer activity in human cancer cell lines resistant to Parental Generation
——————————————————————
5. The research from Egypt shows promising results for binding to DNA
——————————————————————
I doubt Dr. Gorski will be blogging about the above, anytime soon, as it

DOES NOT FIT HIS NARRATIVE
======================================
2000 – Thomas Navarro [3]
——————————————————————
What happened to Donna and Jim Navarro when they chose Burzynski’s treatment over orthodox treatments ?
——————————————————————
4 year old Thomas Navarro diagnosed with medulloblastoma
——————————————————————
Operated on
——————————————————————
Tumor removed
——————————————————————
Scheduled for radiation therapy
——————————————————————
Parents knew he’d be damaged by radiation therapy
——————————————————————
Nobody his age survives this type of tumor anyway after radiation therapy
——————————————————————
Why they decided to go to Burzynski Clinic
——————————————————————
Could NOT treat him because FDA requires failure of radiation therapy for such patients
——————————————————————
Parents decided NOT to take any treatment
——————————————————————
Burzynski asked FDA several times to allow administration of Antineoplastons, because already had successful treatments for some other children without any prior radiation
——————————————————————
5/2001 – developed numerous tumors
——————————————————————
Burzynski suggested to parents they should go for at least chemotherapy
——————————————————————
Went for chemotherapy to one of best centers in the country, Beth Israel Hospital in New York
——————————————————————
Chemotherapy was successful, but he almost died from it
——————————————————————
Severly affected his bone marrow
——————————————————————
Phone call from Thomas’s father telling Burzynski doctors thinking they won’t do anything else for him and Thomas will die within a week because of severe suppression of bone marrow
——————————————————————
Burzynski encouraged father to do whatever possible because such patients may turn around
——————————————————————
He turned around
——————————————————————
About month or two later developed 15 tumors in brain and spinal cord
——————————————————————
When close to death, nothing available, FDA called and allowed Burzynski to treat Thomas
——————————————————————
Treated Thomas
——————————————————————
Survived 6 months
——————————————————————
Tumors had substantially decreased
——————————————————————
11/2001 – ultimately died from pneumonia
——————————————————————
Perhaps professor and chairman of oncology at the Mayo Clinic in Minnesota, Jan Buckner, professor and head of the division of bioethics at NYU Langone Medical Center, Arthur Caplan, chair of the Children’s Oncology Group, an NCI-supported research network that conducts clinical trials in pediatric cancer, pediatric oncologist and professor of pediatrics and pharmacology at Children’s Hospital of Philadelphia, Peter Adamson, David H. Gorski, M.D., Ph.D., FACS, a/k/a GorskGeek, and “Orac”, ALL think that the 15 tumors Thomas Navarro had in his brain and spinal cord, which had substantially decreased under Burzynski’s antineoplaston therapy, were because of Pseudoprogression a/k/a Pseudo-Progression (psPD) and / or pseudoresponse, caused by
chemotherapy ?

Is this what they mean by:

“In reality, the tumor was just returning to its previous size” ?
======================================
Dustin Kunnari [3]
——————————————————————
At 2 ½ years old, Dustin Kunnari had brain surgery
——————————————————————
Surgery removed only 75% of tumor
——————————————————————
Dustin’s parents, Mariann and Jack, were told Dustin would only live 6 months
——————————————————————
Chemotherapy and radiation may extend life slightly, but at very high cost in quality of life with very serious side effects
——————————————————————
Mariann and Jack decided to look into alternatives
——————————————————————
Found out about Antineoplastons
——————————————————————
After only 6 weeks of intravenous treatment, MRI showed he was cancer free
——————————————————————
One year later another tumor appeared on MRI
——————————————————————
By this time Dr. Burzynski had developed more concentrated form of Antineoplastons
——————————————————————
After 5 months tumor was gone
——————————————————————
remained cancer free ever since
——————————————————————
Age 7 – taken off Antineoplastons
——————————————————————
To further complicate matters, oncologist kept threatening parents with a court proceeding to take Dustin away and force him to take Chemotherapy/Radiation treatment
——————————————————————
This continued for a year, even after success with Antineoplastons
——————————————————————
Age 12 at time of 12/2002 interview
——————————————————————
Perhaps professor and chairman of oncology at the Mayo Clinic in Minnesota, Jan Buckner, professor and head of the division of bioethics at NYU Langone Medical Center, Arthur Caplan, chair of the Children’s Oncology Group, an NCI-supported research network that conducts clinical trials in pediatric cancer, pediatric oncologist and professor of pediatrics and pharmacology at Children’s Hospital of Philadelphia, Peter Adamson, David H. Gorski, M.D., Ph.D., FACS, a/k/a GorskGeek, and “Orac”, ALL think that the tumor David Kunnari had, which disappeared under Burzynski’s antineoplaston therapy, were because of Pseudoprogression a/k/a Pseudo-Progression (psPD) and / or pseudoresponse, caused by
surgery ?

Is this what they mean by:

“In reality, the tumor was just returning to its previous size” ?
======================================
Paul Leverett [3]
——————————————————————
5/1999 – diagnosed with glioblastoma multiforme grade 4 brain stem tumor
——————————————————————
Prognosis was would probably be dead before end of 1999
——————————————————————
Orthodox medicine gave him no hope of survival
——————————————————————
Given maximum amount of radiation was capable of receiving
——————————————————————
Slowed tumors growth slightly, but didn’t alter prospects for survival at all
——————————————————————
After research on Internet learned about Dr. Burzynski’s Antineoplastons
——————————————————————
9/1999 – began taking Antineoplastons intravenously, administered by wife Jennie
——————————————————————
After 6 weeks tumor had grown by only 2 %, Glioblastoma’s normally double in size every 2 weeks
——————————————————————
12/2000 – PET scan confirmed complete remission
——————————————————————
Stayed on Antineoplastonsuntil 8/2001 to ensure tumor wouldn’t reoccur
——————————————————————
Just under 20% tumor necrosis remaining in brain stem, which is probably scar tissue
——————————————————————
Oncologist (at MD Anderson, Houston) initially wanted to show scan’s to his hospitals (MD Anderson) tumor review board
——————————————————————
for whaever reason, refused further contact and didn’t go ahead with it
——————————————————————
Perhaps professor and chairman of oncology at the Mayo Clinic in Minnesota, Jan Buckner, professor and head of the division of bioethics at NYU Langone Medical Center, Arthur Caplan, chair of the Children’s Oncology Group, an NCI-supported research network that conducts clinical trials in pediatric cancer, pediatric oncologist and professor of pediatrics and pharmacology at Children’s Hospital of Philadelphia, Peter Adamson, David H. Gorski, M.D., Ph.D., FACS, a/k/a GorskGeek, and “Orac”, ALL think that the glioblastoma multiforme grade 4 brain stem tumor Paul Leverett had, which disappeared under Burzynski’s antineoplaston therapy, were because of Pseudoprogression a/k/a Pseudo-Progression (psPD) and / or pseudoresponse, caused by radiation ?

Is this what they mean by:

“In reality, the tumor was just returning to its previous size” ?
======================================
Crystin Schiff [3]
—————————————————————–
Ric and Paula Schiff about torture their daughter Crystin had to endure during chemotherapy/radiation treatment
—————————————————————–
Diagnosed with perhaps most malignant tumor known, rhabdoid tumor of the brain
—————————————————————–
Historically, there was no case of such a tumor ever having long response to chemotherapy or radiation therapy
—————————————————————–
Received extremely heavy doses of radiation therapy and chemotherapy, because nobody expected she would live longer than year or so
—————————————————————–
Was terribly damaged with this
—————————————————————–
Responded very well to Antineoplastons
—————————————————————–
Complete response
——————————————————————
Died from pneumonia
——————————————————————
Immune system was wiped out, so when she aspirated some food, she died from it
—————————————————————–
Autopsy revealed didn’t have any sign of malignancy
—————————————————————–
Particularly despicable story, because when Ric Schiff asked Dr. Michael Prados, then head of neuro-oncology at University of California at San Francisco Medical Center (UCSF), if he knew of any other treatment besides chemotherapy/radiation for Crystin’s
brain tumor, Prados replied in the negative

But a few years before, he had sent you 14 letters documenting effectiveness of Antineoplastons on Jeff Keller, another patient with brain cancer

Is this true?

Yes, Jeff Keller had extremely malignant brain tumor

had high-grade glioma of the brain; failed radiation therapy and additional treatments

responded extremely well to our treatment

was one of patients whose case was presented to NCI

there was no doubt about his response

Dr. Prados knew about it

If he was dealing with hopeless tumor like Crystin Schiff, why didn’t he call us?

Do you know why Prados did not tell them about Keller’s success with your treatment?

It’s hard for me to tell

It happens that Dr. Prados and Dr. Friedman, who became boss of FDA, came from same medical school

they work closely together, and perhaps there is something to do with general action against us

It would be inconvenient for Dr. Prados to say that treatment works if FDA was trying to get rid of us and when his friend was Commissioner of FDA at that time

Perhaps that’s the connection….
—————————————————————–
Perhaps professor and chairman of oncology at the Mayo Clinic in Minnesota, Jan Buckner, professor and head of the division of bioethics at NYU Langone Medical Center, Arthur Caplan, chair of the Children’s Oncology Group, an NCI-supported research network that conducts clinical trials in pediatric cancer, pediatric oncologist and professor of pediatrics and pharmacology at Children’s Hospital of Philadelphia, Peter Adamson, David H. Gorski, M.D., Ph.D., FACS, a/k/a GorskGeek, and “Orac”, ALL think that the rhabdoid tumor of the brain Crystin Schiff had, which disappeared under Burzynski’s antineoplaston therapy, were because of Pseudoprogression a/k/a Pseudo-Progression (psPD) and / or pseudoresponse, caused by chemo and radiation ?

Is this what they mean by:

“In reality, the tumor was just returning to its previous size” ?
======================================
REFERENCES:
======================================
[1] – 11/15/2013 – Stanislaw Burzynski in USA Today: Abuse of clinical trials and patients versus the ineffectiveness of the FDA and Texas Medical Board (Getting Worse is Getting Better):
——————————————————————
http://scienceblogs.com/insolence/2013/11/15/stanislaw-burzynski-in-usa-today-abuse-of-clinical-trials-and-patients-versus-the-ineffectiveness-of-the-fda-and-texas-medical-board/
=====================================
[2] – 11/11/2013 – “The Amazing Meeting” (I don’t think it means, what you think it says it means): 2 Intellectually and Ethically Challenged Individuals, Twaddle at TAM 2013:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/11/www-amazingmeeting-com-www-randi-org-lanyrd-com2013tam-forums-randi-orgforumdisplay-php/
======================================
[3] – 12/2012 – Interview with Dr. Burzynski, M.D., Ph.D. Biochemistry (12/2002):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/12/httpwww-cancerinform-orgaburzinterview-html/
======================================
[4] – 8/29/2013 – Burzynski Securities and Exchange Commission (SEC) Links:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/29/burzynski-securities-and-exchange-commission-sec-links/
======================================
[5] – 8/13/2013 – Does David H. “Orac” Gorski, M.D., Ph.D, really CARE about Breast Cancer patients?:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/13/does-david-h-orac-gorski-m-d-ph-d-really-care-about-breast-cancer-patients/
======================================

Posted in adverse effects, Antineoplastons (ANP), bias, biased, critique, critiques, critiqued, critiquing, FDA, United States Food and Drug Administration, Gorski ScienceBlogs.com/Insolence ScienceBasedMedicine, Stanislaw Rajmund Burzynski, The Skeptics, USA TODAY | Tagged "14 letters", "2nd generation Antineoplastons", "2nd generation of Antineoplastons have been shown to be at least a THOUSAND TIMES MORE POTENT then Parental Generation", "3rd generation structurally altered Antineoplaston believe will exhibit markedly improved anticancer activity", "3rd generation structurally altered antineoplaston", "50 or 60 tablets a day pretty much all you can take by mouth", "Alexander J. Walt Comprehensive Breast Center", "American College of Surgeons Committee on Cancer", "Ann Karmanos Cancer Center", "Ann Karmanos Cancer Institute", "antineoplaston research", "antineoplaston therapy", "Arthur Caplan professor and head of the division of bioethics at NYU Langone Medical Center", "Arthur Caplan", "Associate Professor of Surgery and Oncology at the Wayne State University School of Medicine, "Barbara Ann Karmanos Cancer Center / Institute", "Barbara Ann Karmanos Cancer Institute", "Beth Israel Hospital in New York", "bone marrow", "brain cancer", "brain cancers", "brain surgery", "Burzynski interview", "Burzynski Securities and Exchange Commission (SEC) Links", "Burzynski’s antineoplaston therapy", "cancer free", "Cancer Liaison Physician for the American College of Surgeons Committee on Cancer", "cell culture experiments", "chairman of oncology", "Chemotherapy and radiation", "Chemotherapy/Radiation treatment", "children without any prior radiation", "Children's Oncology Group", "conventional treatments", "Could NOT treat him because FDA requires failure of radiation therapy for such patients", "Critiquing: Doctor accused of selling false hope to families (USA TODAY NEWS, "Critiquing: Experts dismiss doctor’s cancer claims (USA TODAY NEWS, "Critiquing: Families run out of hope, "Critiquing: Stanislaw Burzynski in USA Today: Abuse of clinical trials and patients versus the ineffectiveness of the FDA and Texas Medical Board (Getting Worse is Getting Better)", "Critiquing: Stanislaw Burzynski in USA Today: Abuse of clinical trials and patients versus the ineffectiveness of the FDA and Texas Medical Board (Josia Cotto)", "Critiquing: Stanislaw Burzynski in USA Today: Abuse of clinical trials and patients versus the ineffectiveness of the FDA and Texas Medical Board (swell inflammation phenomenon)", "Crystin Schiff", "D.H. Gorski", "damaged by radiation therapy", "David Kunnari", "developed 15 tumors in brain and spinal cord", "developed numerous tumors", "Development of 2nd generation of Antineoplastons", "DH Gorski", "DID NOT TELL YOU ABOUT", "DNA binding capacity", "Doctor accused of selling false hope to families", "Does David H. Orac Gorski, "DOES NOT FIT HIS NARRATIVE", "Doesn’t even come close to adverse reactions that experience with chemotherapy", "Don’t see any delayed toxicity once treatment stops", "Donna Navarro", "Dr. Adamson", "Dr. Buckner", "Dr. Burzynski", "Dr. Caplan", "Dr. David H. “Orac” Gorski", "Dr. David H. Gorski Orac”, "Dr. Friedman", "Dr. Gorski", "Dr. Prados", "Dustin Kunnari", "Egypt antineoplaston studies", "Egypt antineoplaston study", "evaluated against A10", "Everything practically goes back to normal within day or two", "exhibit markedly improved anticancer activity on human cancer cell lines resistant to Parental Generation", "Experts dismiss doctor’s cancer claims (USA TODAY NEWS, "Experts dismiss doctor’s cancer claims", "extremely heavy doses of radiation therapy", "Families run out of hope, "FDA requirements", "FINALLY, "glioblastoma multiforme grade 4 brain stem tumor", "glioblastoma multiforme grade IV brain stem tumor", "Glioblastoma’s normally double in size every 2 weeks", "head of neuro-oncology", "high grade", "human breast cancer cell line", "human cancer cell lines resistant to Parental Generation", "immune system", "In addition to original family of Antineoplaston compounds", "Institute for Science in Medicine", "Interview with Dr. Burzynski, "Intravenous infusion can deliver equivalent of 3, "intravenous treatment", "Jack Kunnari", "Jan Buckner professor and chairman of oncology at the Mayo Clinic in Minnesota", "Jan Buckner", "Jeff Keller", "Jennie Leverett", "Jerry Mosemak", "Jim Navarro", "Jose Cotto", "Josia Cotto", "July TAM 2013", "legal duty", "Limitation of how much medicine can take by mouth", "Longest survivor", "M.R.I.", "malignant brain tumor", "malignant tumor", "Mariann Kunnari", "maximum amount of radiation", "Mayo Clinic in Minnesota", "Mayo Clinic", "MD Anderson tumor review board", "MD Anderson", "Medical Director of the Alexander J. Walt Comprehensive Breast Center", "member of the faculty of the Graduate Program in Cancer Biology", "Michael Stravato", "Most patients taking oral formulations", "Most patients who come to us have received prior heavy radiation therapy, "N.C.I.", "National Geographic", "NCI-supported research network", "new piperidinedione A10 analogs", "Nobody his age survives this type of tumor anyway after radiation therapy", "non-profit", "NYU Langone Medical Center", "NYU Langone", "orthodox treatments", "Parental Generation", "Patients may develop skin rash, "Patients who have most advanced type of cancer will require heavy dosages", "Paul Leverett", "Paula Schiff", "Perhaps 15% of patients taking intravenous infusions of Antineoplastons", "PET scan confirmed complete remission", "Peter Adamson chair of the Children’s Oncology Group, "Peter Adamson pediatric oncologist and professor of pediatrics and pharmacology at Children’s Hospital of Philadelphia", "Peter Adamson", "phone call", "PRACTICALLY NO SIDE EFFECTS at all", "prototype A10", "prototype ANP-A10", "Pseudo-Progressions", "Pseudoprogression Pseudo-Progression (psPD) pseudoresponse", "quality of life", "radiation and/or chemotherapy", "radiation therapy", "receive radiation and chemotherapy", "rhabdoid tumor of the brain", "Ric Schiff", "Robert Hanashiro", "Scheduled for radiation therapy", "ScienceBasedMedicine . org", "Securities and Exchange Commission (SEC) filing", "severe suppression", "Severly affected his bone marrow", "spinal cord", "Stanislaw Burzynski in USA Today: Abuse of clinical trials and patients versus the ineffectiveness of the FDA and Texas Medical Board (Getting Worse is Getting Better) http://scienceblogs.com/insolen, "Structural characterization of new antineoplaston (ANP) representatives", "successful treatments", "superior affinity to DNA", "Surgery removed only 75% of tumor", "there was no case of such a tumor ever having long response to chemotherapy or radiation therapy", "Thomas Navarro", "Those who survive longest are patients who previously did not receive radiation therapy or chemotherapy", "Thousand times more potent then Parental Generation", "Treasurer for the Institute for Science in Medicine", "Treatment require strong commitment from patients as must be infused with Antineoplastons for many weeks or months", "tumor necrosis", "Tumor removed", "Tumors had substantially decreased", "turned around", "United States Food and Drug Administration", "University of California at San Francisco Medical Center (UCSF)", "University of Michigan" Gorski http://en.wikipedia.org/wiki/David_Gorski, "USA TODAY NEWS, "USA TODAY", "USA TODAY’s Liz Szabo, "usually die from complications from these treatments", "very high cost", "very serious side effects", "Wayne State University School of Medicine", "Wayne State University", "were several-fold more potent antiproliferative agents than A10", "When give large dosages intravenously, "When give orally, "wiped out", #FAILED, #FAILING, #sciencebasedmedicine, /http://www.usatoday.com/story/news/nation/2013/11/15/stanislaw-burzynski-cancer-controversy/2994561, 000 tablets a day", 15 tumors", 2%, 20%, 3B, 3D, @gorskon, @oracknows, @ScienceBasedMed, A Life for Josia Foundation, A10, about, above, absolutely, Academically, access, action, additional, administered, administration, adverse effects, advise, advises, advising, after, against, ahead, allow, allowed, alter, alternatives, an NCI-supported research network that conducts clinical trials in pediatric cancer", and Robert Hanashiro", another, ANP, anti cancer drug tamoxifen", antineoplaston, antineoplastons, anything, appeared, around, aspirated, attesting, autopsy, available, away, “brain stem”, “Check My Facts”, “Look, “Our only goal is to promote high standards of science in medicine”, “people without balls”, “Personally, “The Amazing Meeting (I don’t think it means, became, before giving him radiation and chemotherapy”, began, believe, believed, besides, bias, Biased, bind, binding to DNA", bioethics, blogging, boss, brain, Burzynski Clinic, called, Cancer, capable, capacity, CAPSULE, Capsules or tablets", case, category, caused, centers, chair, chairman, chance, Chemo, chemotherapies, CHEMOTHERAPY, chemotherapy/radiation", Chief of the Section of Breast Surgery", CHILDREN, Children’s Hospital of Philadelphia, Clinical, Clinical Trials, close, closely, combination, comment, commissioner, Complete Response, complicate, compound, compounds, concentrated, concluding, conduct, conducts, connection, contact, contacted, continued, country, court, cured, D.", D.H.", damaged, daughter, David Gorski, David H. Gorski, dead, dealing, death, decade, decided, despicable, Detroit, developed, DH", diagnosed, diagnoses, diagnosis, diatribe, die, died, dies, disappear, disappeared, division, DNA, doctors, documenting, doubt, Dr. Michael Prados, during, effect, effective, effectiveness, Egypt, else, encouraged, endure, ensure, ever, expected, extend, extremely, F.D.A., Facebook, FACS", father, FDA, Female, food, force, form, found, friend, further, gain, general, given, glioma, gone, GorskGeek, Gorski, grown, growth, HACK, happened, happens, have to watch fluid balance…and electrolyte balance", head, health, heat, higher, historically, hope, hoped, hopeless, hospitals, Houston, http//www.sciencebasedmedicine.org, http://cancerbiologyprogram.med.wayne.edu/, http://cancerbiologyprogram.med.wayne.edu/faculty/, http://cancerbiologyprogram.med.wayne.edu/faculty/gorski.php, http://karmanos.org/Physicians/Details.aspx?sid=1&physician=70, http://med.wayne.edu/, http://med.wayne.edu/surgery/, http://med.wayne.edu/surgery/faculty/DGorski.html, http://ncas.org/2013/02/mar-9-david-h-gorski-quackademic.html?m=1, http://prognosis.med.wayne.edu/article/dr-gorski-named-codirector-of-michigan-breast-oncology-quality-initiative, http://sciencebasedmedicine.org, http://sciencebasedmedicine.org/editorial-staff/, http://sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/, http://scienceblogs.com/, http://scienceblogs.com/Insolence, http://scienceblogs.com/insolence/2013/11/15/stanislaw-burzynski-in-usa-today-abuse-of-clinical-trials-and-patients-versus-the-ineffectiveness-of-the-fda-and-texas-medical-board/, https://stanislawrajmundburzynski.wordpress.com/2013/08/29/burzynski-securities-and-exchange-commission-sec-links/, http://usatoday.com/, http://usatoday.com/story/, http://usatoday.com/story/news/, http://usatoday.com/story/news/nation/, http://usatoday.com/story/news/nation/2013/11/15/, http://usatoday.com/story/news/nation/2013/11/15/burzynski-cancer-science/, http://usatoday.com/story/news/nation/2013/11/15/burzynski-cancer-science/2994731/, http://usatoday.com/story/news/nation/2013/11/15/jeanine-graf-cancer-children/, http://usatoday.com/story/news/nation/2013/11/15/jeanine-graf-cancer-children/2994675/, http://usatoday.com/story/news/nation/2013/11/15/stanislaw-burzynski-cancer-controversy/, http://usatoday.com/story/news/nation/2013/11/15/stanislaw-burzynski-cancer-controversy/2994561/, http://whybiotech.com/?p=3808, http://wsusurgery.com/facultyc3/david-gorski/, http://wsusurgery.com/research-team-dr-gorski/, http://www.cancerbiologyprogram.med.wayne.edu/, http://www.cancerbiologyprogram.med.wayne.edu/faculty/, http://www.cancerbiologyprogram.med.wayne.edu/faculty/gorski.php, http://www.karmanos.org/Physicians/Details.aspx?sid=1&physician=70, http://www.med.wayne.edu/, http://www.med.wayne.edu/surgery/faculty/, http://www.med.wayne.edu/surgery/faculty/DGorski.html, http://www.ncas.org/2013/02/mar-9-david-h-gorski-quackademic.html?m=1, http://www.sciencebasedmedicine.org/editorial-staff/, http://www.sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/, http://www.sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/ “Our only goal is to promote high standards of science in medicine”, http://www.scienceblogs.com/, http://www.scienceblogs.com/Insolence, http://www.usatoday.com/, http://www.usatoday.com/story/, http://www.usatoday.com/story/news/, http://www.usatoday.com/story/news/nation/, http://www.usatoday.com/story/news/nation/2013/11/15/, http://www.usatoday.com/story/news/nation/2013/11/15/burzynski-cancer-science/, http://www.usatoday.com/story/news/nation/2013/11/15/burzynski-cancer-science/2994731/, http://www.usatoday.com/story/news/nation/2013/11/15/jeanine-graf-cancer-children/, http://www.usatoday.com/story/news/nation/2013/11/15/jeanine-graf-cancer-children/2994675/, http://www.usatoday.com/story/news/nation/2013/11/15/stanislaw-burzynski-cancer-controversy/, http://www.whybiotech.com/?p=3808, http://www.wsusurgery.com/facultyc3/david-gorski/, http://www.wsusurgery.com/research-team-dr-gorski/, https://mobile.twitter.com/, https://mobile.twitter.com/gorskon, https://mobile.twitter.com/oracknows, https://mobile.twitter.com/rjblaskiewicz, https://mobile.twitter.com/ScienceBasedMed, https://twitter.com/, https://twitter.com/gorskon, https://twitter.com/oracknows, https://twitter.com/ScienceBasedMed, https://www.twitter.com/gorskon, https://www.twitter.com/oracknows, https://www.twitter.com/ScienceBasedMed, idea, inconvenient, initially, Internet, interview, into, intravenous, intravenously, investigate, investigated, investigation, kept, knew, know, known, later, launch, learned, least, life, live, Liz Szabo, longer, M.D.", malignancy, matters, MD", medical, medicine, medulloblastoma, Michigan, modification, money after cancer treatments (USA TODAY NEWS, money after cancer treatments", moral, MRI, NatGeo, NATION, NCI, negative, network, networks, Niasia Cotto, Nobody, nothing, now, obtained, offers, oncologist, oncology, operated, opinion, or chemotherapy", Orac, Oracolyte, Oracolytes, ORAL, orthodox, panelist, parent, parents, Particularly, passing, patient, patients, peaks, pediatric, pediatrics, perfect, pH, Ph.D, Ph.D. Biochemistry (12/2002) https://stanislawrajmundburzynski.wordpress.com/2013/11/12/httpwww-cancerinform-orgaburzinterview-html/", pharmacology, PhD, pneumonia, possible", presented, proceeding, Professor", professors, promising, prompt, prompted, prompts, prospects, Pseudo-Progression (psPD)", Pseudoprogression, Pseudoprogressions, pseudoresponse, pseudoresponses, psPD, published, purity, RADIATION, radiotherapy, reaching, really CARE about Breast Cancer patients? https://stanislawrajmundburzynski.wordpress.com/2013/08/13/does-david-h-orac-gorski-m-d-ph-d-really-care-about-breast-cancer-patients/", Reason, receiving, refused, remained, remaining, reoccur, replied, repost, requiring, research, researched, researcher, responded, Response, responsibility, responsible, results", Revealed!, rhabdoid, rid, Scan, scar, school, scienceblogs, section, see practically no side effects at all", sent, several, show, showed, shown, sign, significantly, since, slightly, slowed, something, soon, stability, stayed, story, substantially, success, successful, suggested, support, supported, surgery, survival, survived, synthesized, tablet, tablets, take, taking, Tamoxifen, telling, terribly, tested, therapy, they don’t know what to think”, think, thinking, thinks, Thomas will die within a week", threatening, time, times, tissue, together, torture, treat, treated, treatment, treatments, treats, trials, tumor, tumors, turn, twaddle, Twaddle at TAM 2013 https://stanislawrajmundburzynski.wordpress.com/2013/11/11/www-amazingmeeting-com-www-randi-org-lanyrd-com2013tam-forums-randi-orgforumdisplay-php/", Twitter, USA TODAY", USA TODAY)", utilize, virtually, wanted, what you think it says it means): 2 Intellectually and Ethically Challenged Individuals, whatever, which may last for day or two", wife, work | Leave a reply

Search

Recent posts

  • Pete Cohen films Pat and Steve Clarkson January 15, 2014
  • Pete Cohen talks to Steve and Mary Jo Siegel January 14, 2014
  • Pete Cohen talks with Doug Olson January 10, 2014
  • Pete Cohen talks with Burzynski Patient January 8, 2014
  • Dr. Li-Chuan Chin, PhD, National Cancer Institute Scientist (1991-1997) talks about Dr. Burzynski and Antineoplastons January 6, 2014

Archives

Categories

Meta

  • Register
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.com
Blog at WordPress.com.
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy
  • Follow Following
    • Didymus Judas Thomas' Hipocritical Oath Blog
    • Already have a WordPress.com account? Log in now.
    • Didymus Judas Thomas' Hipocritical Oath Blog
    • Customize
    • Follow Following
    • Sign up
    • Log in
    • Report this content
    • View site in Reader
    • Manage subscriptions
    • Collapse this bar